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ABSTRACT
TITLE:
“Association of 25-hydroxy vitamin D levels with vitamin D receptor Taq1
gene polymorphism in Chennai population.” A cross sectional study.
         Vitamin D stands at the frontline of current scientific endeavours, being a topic of
great interest to medical researchers all over the globe. Vitamin D deficiency (VDD) has
been arising as a pandemic around the world. Globally about one billion people are
known to have VDD and it is the most common undiagnosed medical condition
      Vitamin D receptor (VDR) gene is located in the chromosome12cen-q12. Taq1 gene
is present in the 3’UTR (untranslated region), is a T/C nucleotide substitution
(ATT/ATC) in exon IX coding for isoleucine. This could potentially influence the
activity of 1, 25 dihydroxy vitamin D [1, 25(OH)2 D] by mRNA instability or by affecting
the regulation of translation.
AIM OF THE STUDY:
? To determine the frequency of VDR Taq1 gene polymorphism in normal
individuals.
? To correlate the frequency of VDR Taq1 gene polymorphism with 25-
hydroxy vitamin D [25(OH)D ]levels
? To correlate 25-(OH )D with the levels of parathyroid hormone(PTH),
Calcium (Total and Ionized) and Phosphorus
         MATERIALS AND METHODS:
        The study population consists of 100 normal healthy individuals. Fasting venous
blood was collected from each subjects and estimation of 25- hydroxy vitamin D, Intact
PTH assay, total and ionized calcium, phosphorus, albumin, total protein, glucose, urea
and creatinine were done. VDR Taq1gene Polymorphism was examined using PCR based
restriction fragment analysis.
RESULTS:
            Out of 100 samples analysed, the genotype frequency of Taq1 tt accounts for
94%, Tt accounts for 6% and TT accounts for 0% respectively. The genotype
distribution was not found to be in agreement with Hardy-Weinberg Equilibrium.  When
genotypes are analysed with respect to 25(OH) D, no correlation was observed with
respect to Taq1 SNP.
          About 21% having vitamin D deficiency and the remaining were within normal
range. The vitamin D level decreases with increase in parathyroid hormone which is
statistically significant with p value of 0.002. The total calcium is decreased in VDD
subjects.
CONCLUSION:
From this study we conclude that the predominant VDR Taq1genotype is homozygous tt
?genotype and the homozygous TT genotype is not found in this study population. The
prevalence of vitamin D deficiency is about 21%. Also the genotypes  does not correlate
with vitamin D levels.
Key words:
  VDR, Polymorphism,   25-hydroxy vitamin D,   Parathyroid hormone, Genotype, Taq1.
1 
INTRODUCTION 
              To the medical researchers all over the globe vitamin D had become 
topic of interest. Today the world is facing the problem of vitamin D 
deficiency pandemic as evidenced by recent research. 
          Deficiency of vitamin D is a risk factor in humans, right from 
conception and throughout lifespan1. It is one of the common medical 
condition undiagnosed and under treated nutritional deficiency in the world.  
Globally about one billion people are known to have vitamin D insufficiency 
or deficiency2.  
Prevalence of vitamin D deficiency is about 70-100% in general 
population worldwide. In India the increased prevalence of about 50-100% is 
due to low intake of dietary calcium3, 4. In various groups like school children, 
adolescents, pregnant women and health care professionals, vitamin D 
deficiency is highly prevalent. 
           In late 20th century vitamin D is described as conditional vitamin. 
Traditionally it is called as sunshine vitamin. India is a tropical country located 
between 8.4°N and 37.6°N latitude and people living here receive ample 
sunlight throughout the year despite this hypovitaminosis D is common in 
India3,4. 
              Vitamin D is unique, because the nutrient requirement is met by both 
endogenous production from sunlight and exogenously by diet in our body.  
2 
The epidemic of vitamin D deficiency contribute burden to the health system 
in India because of its various implications in health.  
Vitamin D deficiency (VDD) is noticed in both breast fed infants and 
older children.  It is the common cause of rickets universally4. It is called as 
anti -rachitic factor. 
The medical fraternities across the world are curious in realizing that 
vitamin D plays a major role in health and disease. It causes skeletal as well as 
extra skeletal manifestations. Vitamin D not only regulates calcium and 
phosphorus homeostasis but also protects the individuals from many diseases 
like malignancies, chronic infections, and cardiac problems and reduce the 
risk of  autoimmune diseases.  
The study is to impress upon the physicians about the gravity of the 
vitamin D deficiency problem throughout India and to make appropriate 
diagnosis and treatment with care and caution5.  As the vitamin D status is 
improved worldwide it would have remarkable effects on public health, and 
decrease the healthcare expenses for several chronic diseases.  
Vitamin D exerts its action in the body by binding to vitamin D 
receptor(VDR) which is a member of nuclear hormone receptor super 
family.It modulates the transcription of target genes by complexing with 
vitamin D responsive  elements (VDRES) in the promoter region of target 
genes6. 
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Excellent opportunities are provided by genetic studies to relate 
molecular insights with epidemiological data and it gained much interest. 
Polymorphism referred as DNA sequence variations which occur frequently 
in the population and can have only modest and subtle effects.  
Many   polymorphisms are known to exist in VDR gene according to 
recent studies, but the influence of this polymorphism on VDR protein 
function is not known. At the 3’end of the VDR gene three restriction 
fragments length polymorphisms (RFLP) for BsmI, ApaI and TaqI have been 
studied so far. 
VDR gene polymorphisms could potentially influence the binding of 1, 
25(OH) 2 D and the anti-proliferative effects of vitamin. Many studies have 
been reported on VDR polymorphism and its influence on different disease 
throughout the world. On the contrary in our country the reports are minimal.     
A T/C nucleotide substitution (ATT to ATC) leading to a silent change 
at codon 352 (isoleucine) in exon IX is the Taq1 polymorphism7. 
Therefore this study is to find the frequency of VDR (Taq1) gene 
polymorphism by PCR based restriction analysis of normal individuals in 
Chennai and to determine the association of this polymorphism with 25- 
hydroxy vitamin D levels. 
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REVIEW OF LITERATURE 
Gold blatt and Soames discovered that vitamin D is produced by 
irradiation of 7-dehydrocholesterol in skin9. The structure of vitamin D2 and 
D3 was described by Windaus, German chemist after irradiation of ergosterol 
or 7-dehydrosterol. He had been awarded the Nobel Prize in 1928 for his 
work8. Finsen for his discovery that exposure to sunlight is effective in 
treating skin disorder got Nobel Prize in 190352. 
Until late 1960’s the knowledge about the chemistry of vitamin D did 
not advance, while the work of De Luca, Fraser, and Norman established 
vitamin D as a prohormone. It is converted to highly active forms by 
successive hydroxylation at 25 and 1 position. Vitamin D is both a hormone 
synthesized in skin and as a vitamin when taken from dietary sources11. 
BIOSYNTHESIS OF VITAMIN D: 
In nature, Vitamin D are of two different forms: 
Ø Vitamin D2 and Vitamin D3.  
Ø Vitamin D2 is derived from ergosterol called as ergocalciferol. 
Ø Vitamin D3 is called as cholecalciferol. 
Ø When exposed to UV radiation (290 to 310nm) the cutaneous precursor of 
vitamin D, 7-dehydrocholesterol undergo photochemical cleavage of bond 
between carbon 9 and carbon10 of the steroid ring.  
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Ø The resultant previtamin D is thermally labile, over a period of 48 hours 
undergoes temperature dependent non-enzymatic molecular rearrangement 
resulting in production of vitamin D.                                                                                                  
Ø This thermally labile product isomerizes to luminosterol and tachy sterol, 
two biologically inert products. This alternative photoisomerization 
prevents production of excessive amounts of vitamin D with prolonged 
sun exposure23.  
Ø Vitamin D2 differs from D3, double bond present between C22 and C23 and 
methyl group in C24 side chain20. And the two compounds have equivalent 
biological activity in humans and undergo identical metabolic conversion 
to active forms by hydroxylases11. 
SOURCES OF VITAMIN D:  
Vitamin D2 is provide by plant sources and vitamin D3 is provided by 
animal sources . Sources are sun light, diet and supplements. Natural sources 
like cod liver oil, egg yolk, fish, mushroom and fortified foods like milk, 
butter, cheese, yogurts, orange juice are rich in vitamin D41. 
The mode of action of vitamin D can be elucidated by: 
 
1. The endogenous activation of vitamin D  is by sequential hydroxylation at 
C25 and C1 . 
2. Molecular mechanism subsequent to binding of 1,25dihydroxyvitamin D 
[1,25(OH)2D] to a specific Vitamin D receptor (VDR)  known to recruit 
large number of proteins. 
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3. Regulation of expression  of genes involved either in homeostasis of 
calcium or linked to cell proliferation and differentiation 
PHYSIOLOGY OF ABSORPTION, METABOLISM AND EXCRETION: 
Absorption 
Vitamin D taken in dietary form are fat soluble and it is absorbed 
principally in proximal small bowel8. About 80% of vitamin D is incorporated 
with   chylomicrons and absorbed in lymphatic system. It enters the blood by 
a process involving binding to vitamin D binding protein majorly, although a 
small fraction is bound to albumin18.  Defective absorption is seen in 
individuals with malabsorption syndromes like celiac disease, whipple’s 
disease etc11. 
Metabolism of vitamin D: 
Vitamin D from skin and diet can be stored in and released from fat 
cells41. It enters circulation by binding to a specific protein called vitamin D 
binding protein. Vitamin D is not active as such but it undergoes a series of 
metabolic transformations in the liver and kidney to form active metabolite11. 
Vitamin D metabolism involves three main steps:   
Vitamin D is biologically inert and it undergoes consecutive 
hydroxylation in liver and kidneys to form 1,25(OH)2 D, the active metabolite. 
The steps include 
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Ø 25-hydroxylation. 
Ø 1α hydroxylation, and  
Ø 24- Hydroxylation.  
Ø  By enzymes cytochrome p-450 mixed function oxidase located either in 
mitochondria or endoplasmic reticulum19. 
25 HYDROXYLATION: 
The initial step occurs in the liver where vitamin D undergoes 
hydroxylation at 25th position by the enzyme 25- hydroxylase to form 25-
(OH)D or calcidiol5. But it also occurs in extra hepatic tissues in vitro8. 
Hepatic 25-hydroxylation is performed by more than one enzyme 
located either in the microsomes (CYP2D11, CYP2D25, CYP3A4, CYP2R1) 
or in the inner mitochondrial membrane (CYP27A1)12. It is a mixed function 
oxidase for which NADP and molecular oxygen are utilized. 
The most important 25- hydroxylase is CYP2R1. The 25 hydroxylation 
of vitamin D is not a regulated process.  The principal circulating form is 
25(OH) D. Its serum concentration is about 10 - 50 ng/ml and the half life is 
about 15 to 20 days11. It is the excellent measure of nutritional status of 
vitamin D because its levels increase in proportion with vitamin D intake19. 
CYP27A1 is the only mitochondrial 25-hydroxylase having broad 
substrate specificity and is mainly involved in hydroxylation steps in 
cholesterol and bile acid12. In liver disease circulating levels of 25-(OH) D is 
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reduced.  Also in persons taking anti convulsant drugs like phenobarbitone 
and phenytoin reduced levels seen by inducing hepatic microsomal enzymes 
which inactivate vitamin D11. Homozygous mutation of CYP2R1 was 
identified in persons with classical rickets13. 
1 α HYDROXYLATION: 
The second step in metabolic activation is 1α hydroxylation.  25(OH) 
D is inactive biologically and hence it should be hydroxylated further10.  
1, 25(OH)2 D or calcitriol is  formed by hydroxylation in the kidney  by 1α 
hydroxylase on the 1-carbon position of 25-(OH)D. The enzyme 1α 
hydroxylase (CYP27B1) is a mitochondrial cytochrome p450 mixed function 
oxidase. Requires NADP and ferrodoxin for formation of 1, 25(OH) 2D in 
proximal renal tubule. 
The half life is about 4 to 6 hours. Because of its short half life and 
tight regulatory process 1, 25 (OH)2 D is not a valuable marker to assess 
vitamin D status. 1α hydroxylase activity is noticed in other tissues like 
prostate, colon, breast, lung, pancreatic β cells, parathyroid, thyroid, testes, 
ovary, placenta, and cells of immune system lymphocytes and macrophages 
exhibiting autocrine and paracrine actions20.  
This process is a tightly regulated by 1,25(OH)2D itself(negative 
indirect feedback) parathyroid hormone, calcitonin, and insulin like growth 
factor(positive feedback),phosphate, calcium, phosphorus and fibroblast 
growth factor 23 (FGF-23) negative regulation14,15. 
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Parathyroid hormone (PTH) regulates 1α hydroxylase and mRNA 
activity in renal tubules mediated via cAMP by stimulation of 1α hydroxylase 
gene transcription. Restriction of dietary phosphate also known to elevate 
renal 1α hydroxylase activity and mRNA activity. Calcium from diet also 
regulates the activity of enzyme. Other factors like growth hormone, 
glucocorticoids, prolactin and estrogen also influence the renal 1α 
hydroxylase activity11.  
Mutations in 1α hydroxylase gene was reported in pseudo vitamin D 
deficiency rickets ,also called as vitamin d dependent rickets type -1 .It has 
low serum levels of 1,25(OH)2D ,but normal to high levels of 25(OH)D8. 
24-HYDROXYLATION: 
 25-(OH)D (Calcidiol) and 1,25(OH) 2D (Calcitriol) undergo 
hydroxylation at 24-carbon by the enzyme 24-hydrxylase(CYP24A1)  to form 
24, 25 (OH)2 D and 1,24,25-(OH)3 D in kidney, intestine and cartilage.  
CYP24A1 has both 24-hydroxylase and 23-hydroxylase activity, the 
ratio is dependent upon the species. 1, 25(OH) 2 D is also metabolized to 
several inactive products by 23 or 26 hydroxylase. 
The biologically inactive calcitroic acid is formed from the  
24-hydroxylase pathway whereas the 23-hydroxylase pathway ends up in 
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producing the biologically active 1, 25-26, 23 lactone25. All steps are 
performed by one enzyme.  
Calcitroic acid is the final degradation product that is excreted in urine. 
In addition polar metabolites are excreted in bile, some of these metabolites 
are deconjugated in intestine and reabsorbed in enterohepatic circulation18. No 
mutations have been identified in 24 hydroxylase gene so far but over 
expression of this gene may be involved in cancer8. 
TRANSPORT OF VITAMIN D: 
Vitamin D gets absorbed in gut and gets transported by chylomicron 
via the lymphatic system. It gets stored in tissues like muscle and fat8. 
Vitamin D is highly lipid soluble but it has poor solubility in aqueous 
media.   By means of  binding to a specific carrier protein called vitamin D 
binding protein (DBP)  it  gets transported  in blood 26. It gets hydroxylated 
and released as 25-(OH) D in liver. 
EXCRETION: 
The major route of excretion is through bile. Some of it is reabsorbed 
in the small intestine. Vitamin D is converted into more water soluble 
metabolites like calcitroic acid excreted by the kidneys via urine8, 11. 
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FIG: 1   SYNTHESIS OF VITAMIN D 
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VITAMIN D BINDING PROTEIN: 
DBP is the major carrier of vitamin D and its metabolites. It is a α 
globulin of about   molecular weight 52,000 synthesized in  the liver.  
The protein has higher affinity for 25-(OH) D than 24, 25(OH) 2 D and 
1, 25(OH)2 D.  Approximately 88% fraction of 25(OH) D circulates bound to 
DBP, 0.03% is free and rest bound to albumin. In contrast 85% of circulating 
1, 25(OH) 2 D binds to DBP and 0.4%is free and rest binds to albumin23.  
The function of vitamin D binding protein is to retain the serum 
reservoir of vitamin D and modulation of  activity of vitamin D metabolites. 
The function of DBP is to reflect the free hormone hypothesis which states 
that the free fraction unlike protein bound fraction of active vitamin D 
hormone is responsible for biological activity. 
DBP concentration in plasma is 20 times more than the total vitamin D 
metabolites.  Vitamin D binding with DBP have longer half life because they 
are less prone for metabolism in liver and biliary excretion. Unbound fraction 
of vitamin D is responsible for biological activity rather than protein bound 
fraction. The level of DBP is reduced in liver diseases, nephrotic syndrome 
and malnutrition while it is increased on estrogen therapy and its 
concentration doubles during pregnancy8. 
 The cellular effects of 1, 25(OH) 2 D correlate with the free fraction. 
Vitamin D  entry in to renal system  by receptor mediated uptake of DBP in 
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brush border of proximal renal tubules but not by diffusion24,26. Megalin is a 
lipoprotein receptor present in the proximal tubule favors reabsorption of 
DBP and DBP complexed with vitamin D sterols8. 
FACTORS   INFLUENCING CUTANEOUS VITAMIN D SYNTHESIS: 
Vitamin D3 production is affected by the process which significantly 
alters the amount of UVB radiation. The wavelength optimum for the vitamin 
D production is 295 to 300 nm. This is influenced by factors like thick ozone , 
cloud and aerosol optical thickness, particulate pollutants, columns of water 
vapour, cloud cover, aerosols, latitude, altitude28. 
Solar zenith angle (SZA) also influence UVB radiation.  It is the angle 
between the local vertical and observer  line to the sun. Smaller SZA results 
in more intense UV radiation. Factors like time of day, latitude and season 
influence the zenith angle28, 29.   
UVB radiation, below latitude of 35˚ N is sufficient for vitamin D 
synthesis throughout the year. Vitamin D is not produced at higher latitudes 
during winter. Effective UV doses are equated to oral vitamin D3 dose.  
1 MED (minimal erythema dose) exposure  of UV radiation produces a rise in 
serum vitamin D levels that is equal to  that produced on oral  vitamin D 
supplementation of 16,000IU.   
Cutaneous factors like clothing, sunscreen and melanin also influence 
vitamin D synthesis. Cotton and linen blocks UV radiation compared to wool, 
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nylon silk and polyester28.  Light pigmented persons require longer UV 
exposure times than dark  skin people to produce equal amount of vitamin D. 
Cellular basis of actions of vitamin D: 
For most of the biological actions of 1, 25(OH) 2 D it requires a high 
affinity receptor, the VDR24.  VDR is a transcriptional activator, a member of 
steroid hormone receptor super gene family. It modulates transcription of 
target genes. VDR is a phosphoprotein and phosphorylation is important for 
its function11. 
VDR binds 1, 25(OH)2 D effectively at higher affinity even at sub 
nanomolar concentrations35. Regulation of transcription occurs either by 
direct binding of nuclear receptors with the specific response elements or 
influencing transcription by other DNA binding transcription factors. VDR 
expressed in almost all tissues from low to moderate levels but highest 
expression is seen in intestine, kidney, bone, skin and thyroid gland and 
regulates approximately 3% of human genes via its endocrine effect34. 
CLASSIC TARGET TISSUES: 
The primary target tissues for the vitamin D endocrine system are by 
interactions among bone, intestine, kidney and parathyroid glands. Its role in 
mineral metabolism to maintain calcium levels is a complex interplay 
between calcium, phosphate, vitamin D, PTH ,  FGF-23.  
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PTH induces mobilization of bone calcium and stimulates production 
1, 25(OH) 2 D by stimulating 1α hydroxylase activity. By negative feedback, 
1,25(OH)2D acts on parathyroid gland and inhibit secretion of PTH. By 
second negative feedback 1,25(OH)2D limits its own availability by 
decreasing the activity of 1α hydroxylase enzyme while stimulating  the 
enzyme  24- hydroxylase  and induces its own catabolism. 
FGF-23(Phosphatonin) is a phosphaturic hormone produced by 
osteocytes and osteoblast inhibits the activity of NPT2 gene, a newly 
identified target gene for 1,25(OH)2D. The NPT2 gene encodes 
sodium/phosphate co transporter essential for re absorption of phosphate8. 
CALCEMIC ACTIONS OF VITAMIN D: 
IN INTESTINE: 
The principle effect of vitamin D is induction of increased calcium 
absorption across the intestinal epithelial cells. Calcium is absorbed 
throughout the small intestine but the efficiency of absorption is highest in 
duodenum, as the receptors for 1, 25(OH) 2 D is found throughout the 
intestine11. Net absorption of calcium variesdepending upon dietary load of 
calcium, serum concentration of 1, 25(OH) 2 D and bioavailability of dietary 
calcium8. 
Acidification of food in stomach solubilizes calcium and in conditions 
like achlorhydria calcium absorption is decreased31. Finally the ability of 
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intestine to absorb calcium is decreases as age advances this may the reason 
behind the pathogenesis of osteoporosis32.The process of vitamin D sensitive 
transport of calcium across the intestinal epithelial cell occurs by three steps11: 
Vitamin D increases the uptake of calcium through the brush border 
membrane of intestinal microvilli. This is presumed to be the rate limiting 
step in the hormone sensitive transport of calcium. 
1. The entry of calcium from the intestinal lumen into the enterocyte is 
regulated by the epithelial channels TRPV6 and TRPV5 (transient receptor 
potential vanniloid) the intracellular calcium transfer is by calbindin –
D9K8. 
2. An ATP driven calcium pump in the basolateral membrane is capable of 
active extrusion of calcium into the blood against electro chemical 
gradient. Calcium exit could also be driven by a basolateral Na/Ca 
exchanger driven by sodium gradient.  
EFFECTS ON BONE 
            Vitamin D is needed for growth of normal skeleton and bone , both in 
utero and  childhood as well as for maintenance of   skeleton  in  adults . 1,25 
(OH)2 D has dual effects on bone: 
1. Stimulate osteoclastogenesis , bone resorption. 
2. Modify osteoblast function and bone mineralization. 
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The overall effects of vitamin D on bone are more complex. From the 
observations made in humans it is clear that excess 1, 25(OH) 2 D enhance 
osteoclastogenesis and bone resorption while deficiency of vitamin D or 
resistance impairs bone matrix mineralization and osteoblastic activity is 
stimulated8. 
The coordinated actions of calcium and 1, 25 (OH) 2 D with VDR is 
required for growth plate development. 1,25(OH)2D regulates 
osteoclastogenesis by reciprocal regulation of receptor activation of NF-kB 
ligand (RANKL) and osteoproteregin (OPG) Expression of RANKL on the 
surface of osteoblasts is increased by VDR26. 
RANK on immature osteoclasts binds to the receptor activator RANKL 
promotes the cells to mature and combine with other precursor osteoclasts to 
form mature multinuclear osteoclasts. 
Bone remodeling, is an integrated process done by interactions 
between osteoclasts and osteoblasts.  1, 25(OH) 2 D, PTH and prostaglandins 
stimulates RANKL expression but and 1,25(OH)2D inhibits osteoprotegrin 
production with increase in osteoclastic activity. 
Deficiency of vitamin D causes secondary hyperparathyroidism 
resulting in decreased level of phosphorus. For mineralization of bone, 
calcium and phosphorus product should be adequate. Mineralization defect 
caused by low normal serum calcium and phosphorus concentration leading to 
rickets in children and osteomalacia in adults13. 
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IN KIDNEY: 
The kidney plays a major role in metabolism of 1, 25(OH)2 D and 
reabsorption of calcium and phosphate .The proximal tubule of kidney is the 
central tissue for 1α hydroxylation of 25(OH)D. The 1αhydroxlase activity is 
reduced in chronic renal failure which ultimately results in renal 
osteodystrophy. 1, 25(OH) 2 D also increase the distal tubular reabsorption of 
calcium. TRPV5, Calbindin 9K and 28K and plasma membrane ATPase are 
involved8. 
1, 25 (OH) 2 D enhance phosphate reabsorption in proximal tubule of 
kidneys. It plays a role in phosphate homeostasis both PTH and FGF-23 in 
complex interplay with 1, 25 (OH) 2 D are able to reduce reabsorption of renal 
phosphate. 
The effects of 1,25(OH)2D on transport can be conceptualized as 
serving to  maintain availability of phosphate for mineralization of bone by 
diminishing renal excretion and enhancing intestinal absorption. In Vitamin D 
deficiency calcium absorption is impaired. On giving vitamin D supplements 
it restores a normal threshold for renal calcium reabsorption and the renal 
tubule is sensitized to PTH 27. 
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FIG:2 CALCEMIC ACTIONS OF VITAMIN D    
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NON CALCEMIC ACTIONS: 
Vitamin D is essential not only for maintaining bone and skeletal 
health but also play an important role in non skeletal biologic process. The 
virtual ubiquitous expression of VDR in all nucleated cells, the presence of 1α 
hydroxylase in different tissues like heart, brain, stomach, gonads, skin, 
pancreas, colon, placenta, vascular endothelium, and immune system apart 
from kidney.  
And very large number of genes that are under direct or indirect 
control of 1,25(OH)2D all point toward a more universal role for the  
vitamin D endocrine system than just regulation of calcium, phosphate, bone 
metabolism8.                                  
Vitamin D and cancer: 
 1,25(OH)2D  has a potent role in preventing progression of cancer by 
reducing cell proliferation, promoting cell differentiation, apoptosis of cancer 
cells, reducing angiogenesis ,inflammation, and metastasis18. vitamin D plays 
a protective role in certain cancers like breast cancer, colon cancer, breast 
cancer. 
The protective role of vitamin D in cancer is as follows57: 
Ø It stimulates transcription of p21 which is a cyclin dependent kinase 
inhibitor acts by suppressing the cells of monocyte-macrophage lineage 
and promotes their differentiation. 
Ø Vitamin D stimulates cyclin dependent kinase inhibitor p27. 
Ø Vitamin D inhibit TGF (Tumor growth factor) which stimulates 
proliferation of tumor cells. 
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Ø Vitamin D and VDR prevents cancerous cell cycle progression at G1-G0 
transition , which  in turn reduces the rate of cell proliferation24. 
Ø  It exerts  anticarcinogenic effect by down regulation of  Bcl-2  an anti-
apoptotic gene and up regulates  Bax, a pro-apoptotic protein and 
telomerase reverse transcriptase41,40. 
Ø Vitamin D inhibits proliferation of leukemic cell lines and thereby 
increasing maturation and decreasing aggressiveness of potential leukemic 
cells. Therefore, vitamin D is helpful in the treatment of leukemia. 
Ø  Other effects involve cancer cell death, block tumor growth, induces 
antioxidant mechanisms and repair of DNA41. 
By regulating estrogen and androgen receptor signaling it inhibit the 
tumor growth of breast and prostate cancer. 
Vitamin D and Cardiovascular disease: 
The underlying mechanism by which vitamin D offer protection in 
development of atherosclerosis is by VDR present in vascular endothelial 
smooth muscle inhibit macrophage cholesterol uptake, decreased proliferation 
of vascular smooth muscle endothelial expression of adhesion molecules is 
reduced, and release of cytokines from lymphocytes also inhibited41. 
Endothelial dysfunction may be due to inadequate vitamin D intake, 
impaired vascular compliance, enhanced inflammation, or high levels of PTH 
and renin-angiotensin (RAS). The negative feedback of vitamin D on RAS 
plays a key role in regulating blood pressure, electrolytes and volume 
homeostasis24. 
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Many prospective studies states, there exist an inverse relation with 
vitamin D levels and cardiovascular disease. Vitamin D could impact 
cardiovascular events either by VDR in smooth muscle vasculature or cardiac 
muscle or indirectly by promoting calcium absorption at the expense of lipid 
absorption or excretion in gut.  
As shown in various epidemiological studies there is also an 
association between vitamin D and hypertension. On vitamin D 
supplementation or exposure to UV radiation there will be an increase 
25(OH) D levels by increasing RAS activity which in turn have 
antihypertensive effects24. 
VITAMIN D AND   DIABETES: 
1,25(OH)2D having  immunomodulator  activity , implicated in 
prevention of type1and type 2 diabetes mellitus by reducing cytokine 
production, proliferation of lymphocytes, and  destruction of beta cells of 
pancreas38.  
Autoimmune destruction of β cells of pancreatic islet cells results in 
Type-1 DM. The mechanism of action: 
Ø Inhibition of dentritic cell maturation. 
Ø Suppress the antigenic property of macrophages. 
Ø Modulation of CD4 lymphocytes. 
Ø Inhibition of interferon γ and interleukin2 production. 
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β cells of islets of langerhans  express VDR and  vitamin D  stimulates 
the production of insulin secretion . Deficiency in vitamin D results in insulin 
resistance38. 
Obese persons having low 25(OH) D are more prone to get diabetes 
and metabolic syndrome.VDR expressed in adipocytes and 1, 25(OH)2 D 
promotes lipogenesis while lipolysis is decreased25. 
Improving the status of vitamin D leads to increased insulin sensitivity. 
Children on vitamin D supplements have 30% reduction in risk of type1 
diabetes as shown in observational studies5. 
Vitamin D and immune function: 
Regulation of immune system by vitamin D is essential for protecting 
against infectious diseases. Presence of VDR in macrophages, dentritic cells, 
B cells and T cells regulates both the adaptive as well as innate immunity. On 
exposure to foreign antigens Vitamin D is capable of stimulating an 
antimicrobial peptide called cathelicidin. Thus cathelicidin plays a key role in 
innate immune defense mechanism and regulate the transcription of VDR 
gene57. 
1, 25(OH) 2 D in adaptive immune response acts by modulating the 
functions of dentritic cells. It inhibits maturation of dentritic cell  and 
generates synchronized action by expression of cytokines like (IL-1, IL-2,IL-
12,IL-17,IFN-γ ) on T cells and the genes like(MHC class II and co signaling 
proteins) needed for antigen presentation . The global effect of these immune 
modulating action is thus a down regulation of acquired immune system8.  
T-lymphocyte proliferation is also inhibited and the expression of TH1 is 
shifted to TH236.  
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Vitamin D and skin: 
The   combined presence of vitamin D production, 25 hydroxylase, 1α 
hydroxylase and VDR expression in the epidermis suggest the existence of 
unique vitamin D intracrine system in which UVB irradiated keratinocytes 
may supply their own needs for 1,25(OH)2 D. The antiproliferative and 
prodifferentiation activity of VDR ligand is exerted on epidermal 
keratinocytes. The more differentiated keratinocytes acts a barrier by 
preventing water loss and protects from environmental microbes. 
As cells differentiate they start to express keratins 1 and 10, as well as 
involucrin.  In addition some proteins and lipids are expressed to form the 
cornified envelope which  acts as a epidermal barrier. This barrier protects 
from toxins and infectious agents by acting as a host defense. The dermis is 
exposed to foreign antigens when the barrier gets disrupted. 1, 25(OH) 2 D  by 
its ability to inhibit proliferation and immune activity suppression  have been 
used for treating  psoriasis , a disorder of  hyper proliferative and abnormal 
differentiation25. 
Chronic exposure to sun results in development of non-melanoma skin 
cancer by gene alterations, stress, and proinflammatory actions16. On 
supplementation with vitamin D there is a decrease in risk of recurrence of 
melanoma compared to those not treated with vitamin D as stated in Newton-
Bishop et al. 
Other diseases: 
           Risk of Depression ,  Alzheimer’s disease, and Schizophrenia  are high 
in vitamin D deficient persons. The risk of peripheral vascular disease is 
decreased by 80% in persons with sufficient vitamin D 24. 
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ASSESSMENT OF VITAMIN D STATUS: 
25(OH) D is the best diagnostic marker for assessing the vitamin D 
status and it may vary among different populations8. Because 25(OH) D is 
more stable and having half life of about 15-20 days being a most important 
key indicator of  evaluating disorders of mineral metabolism. 
           Endocrine society and IOM (Institute Of Medicine) states vitamin D 
status based on  levels of 25-(OH )D: 
Ø vitamin D deficiency ------>  < 10ng/ml  
Ø vitamin D insufficiency   ---->  21-29ng/ml  
Ø Vitamin D sufficiency  ------ > 30 ng/ml  and the range being   preferred   
is 40-60 ng/ml. Till 150ng/ml vitamin D toxicity does not occur41. Still, 
there exist a controversy in defining vitamin D deficiency or sufficiency 
based on 25(OH) D levels19.  
           Other factor defining vitamin D status is suppression of parathyroid 
hormone. When 25 (OH) D levels are about 30ng/ml there exists stability in 
PTH suppression thus the rationale of selecting optimal vitamin D as 30ng/ 
ml. There is evidence of low 25(OH) D, inspite of PTH level being normal  
and on the contrary PTH is not suppressed when 25(OH) D  is increased39. 
Vitamin D  functional status is also evaluated by 25(OH) D level that 
result in maximum  calcium absorption from intestine.                           
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Before labeling the person as vitamin D deficient PTH and calcium 
should be evaluated. Vitamin D level alone is not enough to predict the 
deficiency as PTH level is normal in 50% of population having decreased 
vitamin D levels45. A simplistic classification of vitamin D status is suggested 
in the Mayo Clinic proceedings 2011. 
Classification of vitamin D status based on 25-(OH) D8, 52. 
≤10ng/ml ----à Deficient 
11-20 ng/ ml ----à Insufficient 
>20ng/ml -----à optimal 
EPIDEMIOLOGY:                  
The National Health and Nutrition Examination Surveys 2001–2006 
had shown that 33% prevalence of vitamin D deficiency. 
Vitamin D levels (<9 ng /mL) is prevalent in more than 35% of Indian 
school children. Over 80% of pregnant women in India had 25(OH) D levels 
<22.5 ng/ml21.  
Prevalence of hypovitaminosis D as per International Osteoporosis 
Foundation  in North India are neonates 96%, 91% of healthy school girls, 
78%of hospital staffs and 84% of pregnant women. In South India the 
prevalence of vitamin   D   deficiency is 40% in males and 70% in females45. 
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Modernization, evolutionary changes, clothing, hours spent indoors, 
obesity, environmental pollution, and use of sunscreen result in reduced 
vitamin D synthesis33. 
ASSAY FOR VITAMIN D AND METABOLITES 
There are many methods available commercially for determination of 
vitamin D status. 25(OH) D and 1, 25(OH) 2 D are the two metabolites used 
for assay of vitamin D status.  Although 1, 25(OH) 2 D  is the most active 
form it is not measured but assay of  serum 25(OH) D is the choice because it 
is the major circulating metabolite, having longer half life and it reflect the 
vitamin D status38. This measurement helps for monitoring vitamin D therapy. 
The assay for 25(OH) D53: 
Ø High pressure liquid chromatography (HPLC). 
Ø Liquid chromatography Mass Spectroscopy  
Ø Radioimmunoassay(RIA) 
Ø Enzyme immunoassay (EIA) 
Ø Competitive protein binding assay(CPBA) 
Ø Automated chemiluminescent protein binding assay(CLPBA) 
Ø Chemiluminescent immunoassay (CLIA). 
The most commonly used assays to determine vitamin D status are 
radioimmunoassay and chemiluminescence protein binding assay. Among 
various assays available, variability exist between different assays among 
laboratories even when using the same assay resulting in false high or  
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low values. To improve the variability among methods, a standard  
reference material is available for standardization of values across  
labs to  enhance accuracy and reproducibility38. The widely  
accepted reference method for  25-(OH)D assay is LCTMS  
(liquid chromatography tandem mass spectrometry). 
RECOMMENDED DAILY INTAKE OF VITAMIN D (RDA): 
All the breast fed infants should receive 400 IU/day of vitamin D 
supplements as recommended by American academy of pediatrics. Non breast 
fed infants have to receive 400IU / dayof supplements until they receive 
Vitamin D fortified milk. The RDA for children and adolescents are 
approximately 600IU/day recommended by Food and Nutrition Board54. 
       The serum level of 25(OH)D increases by 0.6-1.0 ng/ml  for every 
100IU/day. The IOM(Institute of Medicine)  recommends the increase of 25-
(OH)D to 20ng/ml for maintaining adequate bone health41. 
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CLINICAL CONSEQUENCES OF VITAMIN D DEFICIENCY: 
SKELETAL: 
           1.    Rickets is known to occur in children of age less than 2-3 years. It 
is characterized by defective mineralization of the skeleton in the growth plate 
and metaphysis adjacent to it. 
Symptoms like pain in bones of legs, delayed age of standing or 
walking, delayed growth, and frequent falling. On physical examination – 
enlarged anterior fontanalle, frontal bossing, craniotabes, delayed tooth 
eruption, widening of metaphysis (enlargement of wrist and ankles) are seen8. 
Diagnosis should be confirmed by X-ray, showing osteopenia, cupping 
and fraying of metaphysis, and fuzziness of zone of calcification. These 
changes are seen in active growth plate namely distal ulna and femur, 
proximal and distal tibia. Biochemically serum alkaline phosphatase level will 
be elevated, phosphorus will be low or normal, calcium will be low and 
25(OH) D will be <5ng/ml39. 
2. OSTEOMALACIA:   
Defective  mineralization of the mature skeleton. The un mineralized 
osteoid will be deposited at sites other than metaphysis is referred as 
osteomalacia. Bone pain is the characteristic symptom. Proximal muscle 
weakness and instability of gait are the other symptoms. X ray show pseudo 
fractures of pelvis, metatarsals, femur and scapula. Biochemical feature is 
elevated alkaline phosphatase, PTH, decreased calcium, phosphorus and 
vitamin D39. 
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3. Osteoporosis, 
4. Increased risk of fracture hip and vertebra. 
NON SKELETAL38: 
Ø Respiratory diseases like influenza, tuberculosis and chronic respiratory 
disease such as cystic fibrosis, interstitial lung disease and chronic 
obstructive lung disease. 
Ø  Cardiac hypertrophy, myocardial infarction, stroke, cardiac failure 
Ø Autoimmune encephalomyelitis, thyroiditis , rheumatoid arthritis. 
Ø Renal fibrosis 
Ø Diabetes mellitus type 1& 2 
Ø Cancer of breast, colon and prostate, leukemia and other 
myeloproliferative disorders. 
Ø Multiple sclerosis. 
Ø Mental illness. 
VDR STRUCTURE AND FUNCTION: 
          VDR belongs to the family of nuclear hormone receptor super family. It 
plays a role in maintaining calcium and phosphorus homeostasis, regulation 
of cellular proliferation, mediates apoptosis and  modulate immune responses. 
It acts a ligand dependent transcription factor that is able to activate or repress 
target genes by inducing conformational change within the receptor. VDR 
enhances heterodimerization with RXR (retinoid X receptor) to form VDR –
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RXR heterodimer and it induces binding with vitamin D responsive elements 
(VDREs) which is located at the promoter region of target gene . 
        VDR having molecular mass of approximately 48 kDa consist of 427 
amino acids. Based on function it is divided into various domains59. 
Ø  A/B domain:  Highly variable domain present in the amino terminus 
having 20 amino acids. Concerned with ligand induced VDR 
transactivation. 
Ø C domain:    is the DNA binding domain present between 21 to 92 amino 
acids. 
Ø D domain:  is the flexible hinge region located from 93 to 123 amino 
acids connecting the DNA binding domain and the ligand binding 
domain.. 
Ø E domain: is the ligand binding domain between amino acids 124 to 427. 
Dimerization and transactivation are concerned with this domain. 
Ø F domain: not conserved domain. 
STRUCTURE OF VDR: 
A/B DOMAIN: 
This domain is short compared to other member of nuclear receptor 
family. It is concerned with transcriptional activation function. Certain co 
activators (p160) and DRIP complexes interact with A/B domain and induce 
domain mediated transactivation. The receptor present in the A/B domain 
contributes for constitutive ligand independent transactivation, activattion 
Function-1(AF-1).  The ligand binding, DNA binding or transactivation  of 
33 
A/B domaim will not affect the autonomous transcription activation of A/B 
domain58. 
DNA binding domain59: 
It is the most conserved domain. It consists of highly conserved amino 
acid residues (C24to M89) and 44 variable residues (F16 to I23 and M90 to S125). 
It have two zinc finger motifs each of it is having four cysteine 
residues coordinated tetrahedrally with zinc atoms. Zinc and cysteine residues 
are necessary for maintaining three dimensional structure of DBD. Zinc finger 
motifs form the core structure of DBD and each core is composed of two 
helices (helix1 and helix 2).  
These two helices are oriented at right angles to each other and each 
serves separate functions. 
Helix1 is concerned with specific binding to the major groove of 
hormone response elements on DNA and  helix-2 for receptor dimerization . 
FIRST ZINC FINGER MOTIFS59: 
· Made of 22 amino acid residues (C24 to K45). Constitutes P box and S 
box.  It is involved in carrying out two functions namely dimerization and 
VDRE binding. 
·  Recognition helix is formed by P box. 
·  R49 and K53 referred as S box.  
· S box is involved in both heterodimerization and VDRE binding.  
· Formation of dimer with RXR by both N37 and S box. 
· V26, R50, P-box, S-box participate in binding with vitamin D response 
elements. 
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SECOND ZINC FINGER MOTIFS: 
· Consist of 21 amino acid residues (C60 to R80) and adjacent amino 
acids (Q77 to R80), (L81toI87). Of which the aminoacid residue 
forming structure of VDR homodimers are P61, F62, H75. 
· The three residues forming upstream VDR are P61(Pro61), F62 
(Phe62) and H75(His75).  
· The downstream of VDR N37 (Asn37), E 92(Glu92), F93 (Phe93) 
form DBD interface. They are forced together by vanderwaals forces.  
· The VDR DBD was unable to interact with VDIR (VDR interacting 
repressor)in mutation where proline replaced by threonine. D box of 
second zinc finger motifs causes transrepression of VDIR having weak 
dimerization function. 
 C-Terminal Extension of VDR DBD: 
          Consists of 36 amino acid residues (M90 to L95) and it is the addition 
of VDR DBD. The contiguous 6 amino acid residues (M90 toL95) is  called 
as the T box. It is limited to form dimerization interface for VDR- RXR 
interaction to occur. Of the six amino acid residues of T box K91 and E92 
form salt bridges with D39 and R38 in RXR, while F93 and I94 takes part in 
all functions of CTE. 
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LIGAND BINDING DOMAIN (LBD)55 : 
LBD is a multifunctional domain involves: 
Ø Binding of 1,25(OH)2D ligand 
Ø Interaction with co repressors and co activators  
Ø Strong heterodimerization with RXR. 
The ligand binding induces conformational change that enhances 
dimerization and transactivation interfaces. All these together are essential for 
regulation of transcriptional activities. 
Analysis by three dimensional structures indicates that LBD forms three 
structures based on the ligand binding state of receptors. 
1. Apo receptor without ligand. 
2. Holo agonist and antagonist receptor with agonist ligands 
3. Holo agonist and antagonist receptor with antagonist ligands. 
The receptor binding induces structural changes within the ligand 
binding domain. The most striking conformational change is seen in  
C-terminal helix-12, is the ligand dependent activation function (AF-2), it gets 
repositioned on ligand binding. In Apo receptor the ligand binding cavity is 
open and the helix-12 is exposed whereas in holo receptor the helix-12 will be 
rotated back. In addition minor structural changes will be seen in helices H3, 
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H6, H11. These changes produce receptor by disrupting binding of co 
repressors and generate surfaces for interaction with co activators and activate 
transcription. 
Antagonistic ligands bind in the same ligand binding pocket as agonist 
ligands. It prevents correct assembly of helix 12 and disrupts binding of 
coactivators and inactivates transcription58. 
VDR is unique among other nuclear hormone receptor super family 
(NHR). Unlike NHR it contains large insertion domain connecting H1 and H3 
and encoded by additional exon in VDR gene. 
The crystal structure of LBD describes that helix-12 is critical for 
ligand binding and transactivation. H12 is stabilized by hydrophobic amino 
acid residues of helices H3, H5, H11. This in turn stabilized by two polar 
interactions. One is by salt bridge betweenLys-264(H4) and Gl5u-420 and 
other is hydrogen bond between Ser-235(H3) and Thr415. Some of the 
residues which stabilize H12 also interact directly with 1,25(OH)2D (Val-234, 
Ile-268, His-397, and Tyr-401) .This explains that position of  H12 is 
controlled by1,25(OH)2D. 
VITAMIN D RESPONSE ELEMENTS: 
High affinity interaction between DBD of VDR with specific DNA 
sequences in the promoter region of 1, 25(OH)2D target genes called as 
vitamin D response elements (VDREs)24. It can be classified as positive 
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VDREs (DR3 and DR4type and ER9) and negative VDREs (DR3 n VDRE 
and 1α n VDRE). 
VDREs of positively regulated genes are direct repeat of two 
hexameric binding motifs separated by a spacer of 3 or 4 nucleotides (DR3 
and DR4). Or they may be the everted repeats separated by a spacer of 6 or 9 
nucleotides namely ER6 and ER9 respectively. 
DR3 is the cognate VDRE and is the common type.  It contains 
consensus sequence  5′-AGGTCA-3′, separated by a spacer of 3 nucleotides 
to which  RXR-VDR bind the 5’ half site and  3’ half site respectively form 
heterodimer and target VDRE structure8. 
DBD does not form dimer in the absence of target DNA .On binding to 
ligand dimer gets strengthened. Unliganded VDR forms homodimer on 
binding to response elements. VDR forms heterodimer with RXR on binding 
of ligand. 
Parathyroid hormone-related peptide (PTHRP) gene is also mediated 
by VDR-RXR heterodimer, down-regulatory by binding directly to a  16-bp 
sequences which is almost perfect repeat separated by a 3-bp nucleotides 59. A 
non-consensus(GGGTGGA) direct repeat  is located in 3-bp upstream of this 
motif, and  it is called DR3-liked nVDRE 
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Another novel nVDRE is 1α nVDRE is involved in down regulation  
of 25(OH)D 1α hydroxylase(CYP27B1)gene by 1,25(OH)2D. Here the VDR- 
RXR donot bind directly.  By means of VDIR (VDR interacting repressor) 
another  transcription factor, helps in binding of  liganded VDR- RXR with 
1α nVDRE34. 
Recently, based on VDR interaction with co regulators provides new 
insights for positive and negative modulation of VDR mediated transcription. 
Two domains serve as adaptor surfaces necessary for VDR-co 
regulator interactions. 
1. Region located between residues 244 and 263. This residue form part of 
binding interface with transcriptional co activators. It is highly conserved 
residue. Its alteration compromises transactivation.  
2. AF-2 or Activation Function corresponds to the helix 12 (residues 416-
422). It undergoes conformational change on ligand binding and allows 
recruitment of VDR interacting proteins like RNApolymeraseII, 
Transcriptional initiator complex and nuclear transcriptional coactivators. 
Removal of AF-2 domain eliminate the transcriptional activity of 
1,25(OH)2D-VDR transcriptional activity24. 
TRANSACTIVATION55:     
The regulation of gene transcription involves three classes of proteins: 
1. Basal transcription factors à serve to initiate transcription of protein 
coding genes. 
2. DNA binding transcription factors à precise control of transcription by 
VDR. 
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3. Transcriptional coactivators  à provide protein –protein contacts between 
basal transcription factors and DNA binding factors 
Transcriptional coactivator complex involved in nuclear receptor 
mediated    transcription mechanism are:     
  1 à   ATP dependent chromatin modeling                                               
  2 à Interaction with transcription  factors and  RNA Polymerase II   
  3 à  modification of histone tails 36.   
MOLECULAR MECHANISMS OF VDR IN THE CONTROL OF 
GENE TRANSCRIPTION: 
        1, 25(OH) 2 D interacts with VDR, initiates the series of events which 
either activates or repress gene transcription. The nucleosomal repression is 
released and gene transcription is initated. 
COVALENT MODIFICATION OF DNA: 
               Transcription of genes is repressed by dense packing of DNA by 
limiting the access of transcription factors and RNA polymerase II to the 
binding site. Covalent modification of lysine at the amino terminal histone tail 
neutralize their positive charge thereby the negatively charged DNA attraction 
towards it is neutralized. 
          The binding of VDR to the hormone response elements in the promoter 
region of vitamin D response genes is the initial step for transactivation. 
Nuclear hormone receptors have the ability to bind DNA although it is wound 
around histone core. Ligand binding to hormone receptor induces 
conformational change in the DNA there by  releasing nucleosomal 
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repression. It promotes receptor dimerization and creates new surfaces on the 
receptor for binding coactivator molecules to initiate the cascade of 
transcription events. 
CO ACTIVATORS: 
Two steps to be regulated by co activators in target gene transcription: 
1. Remodeling of chromatin structure to facilitate binding of other co 
activators and RNA Polymerase II. 
2. Recruiting protein complexes that interact with subunits of RNA 
Polymerase II by stabilizing the preinitiation complex58.  
Two enzyme complexes plays role in transactivation are: 
Ø Histone Acetyl Transferases (HAT) 
Ø ATP dependent chromatin remodeling factors. 
HISTONE ACETYL TRANSFERASES (HAT) 
Histone acetyl transferases modify the structure of chromatin by 
catalyzing acetylation of the lysine residues present in the N-terminal tails of 
histones. These include steroid receptor coactivators (SRC) family members 
like SRC-1, SRC-2, SRC-3, CBP(CREB binding protein/p300) and pCAF 
(p300/ CBP associated factor) Acetylation of histones is a dynamic process. 
The mechanism possible for the reversible activation and repression of 
transcription is because of hyper and hypo acetylation of lysine residues. 
Hyper acetylating histones within transcriptionally active chromatin have 
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rapid turnover half life of few minutes whereas the hypo acetylating histones 
of transcriptionally silent regions have less rapid turnover. 
SKIP (SKI-interacting protein)/ nuclear receptor(NR) coactivator 
(NCoA)-62 synergized with SRC-1 and SRC-2 to induce RXR-VDR 
mediated ligand dependent transactivation58. 
SRC family members, CBP/p300, NcoA-62, TATA binding associated 
factors act as transcriptional coactivators and strongly potentiate ligand 
dependent activation of transcription by VDR. 
ATP MEDIATED CHROMATIN REMODELLING FACTORS: 
The co activators like SWI/SNF, ISWI, and Mi-2 are involved in 
remodeling of chromatin catalyzed by uncoupling of ionic interactions 
between histones and   DNA by ATP hydrolysis.  
This complex is involved in initiation of transcriptional activation by 
altering the chromatin which facilitate tight binding of NHR to the hormone 
response elements makes the histone tails accessible to the HAT complexes. 
Also mediate final event in initiation process by binding of transcriptional 
factors to the DNA template. In addition this complex mediates 
transcriptional repression by changing the conformation of chromatin from 
open state to closed state58. 
MEDIATOR COMPLEXES: 
TRAP/ DRIP (vitamin D receptor interacting protein) are the mediator 
complexes which recruit components to the preinitation complex by acting as 
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a link between ligand activated receptor and RNA polymerase II  instead of 
modifying the structure of chromatin. 
COREPRESSORS 
 
NcoR-1, NcoR-2, and hairless are the co repressors that engage in 
histone deacetylase activity. Then it deacetylate the lysine residues present in 
the N-terminal portion of histone tails. It suppresses transcription by 
chromatin compaction and gene silencing42. 
REGULATION OF VDR MEDIATED GENE TRANSCRIPTION:  
VDR is the ligand dependent transcription factor that can modulate 
transcription of VDRE responsive genes in three different ways: 
1. It can positively regulate the expression of certain genes by binding to 
VDRE present in their promoter regions. 
2. It can negatively regulate the expression of genes by binding to negative 
VDRE. 
3. Inhibit the expression of genes by antagonizing the action of transcription 
factors such as NF-AT, NF-κB. 
Genes that contain VDRE in their promoter regions are: osteocalcin, 
osteopontin, RANKL and carbonic anhydraseII involved in extracellular bone 
matrix formation and bone remodeling. 
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Genes that contain VDRE in their promoter region and show vitamin D 
dependent up regulation in their expression are β3integrin, p53, calbindin9k, 
24-hydroxylase etc.  Genes that are negatively regulated by vitamin D are by 
two mechanism. 
1. By binding to n VDRE in promoter region. Example PTH and PTH-RP 
2. Bytranscription factor antagonism (AntiNFκB and AntiNF-AT).This is 
responsible for the anti-inflammatory and antiproliferative actions of 
vitamin D. 
The genes having anti inflammatory actions are IL-2, IL-12, IFNγ, 
TNFα, GM-CSF. And those having anti proliferation actions are EGF-R, C-
myc, K19. 
The classic VDR bound with 1, 25(OH) 2 D can initiate both traditional 
genomic response as well as non-genomic response which is rapid signaling 
cascade.  
FIG:1 B illustrates how   hormonal ligand  could be  influencing VDR  to 
interact efficiently with its partner RXR , VDRE and with coactivators. The 
steps involved are: 
1. 1, 25(OH)2 D3  ligand present  in the VDR genomic pocket (GP) produces  
a  conformation which creates a cleft  in the position of helix 12 at the  
C-terminus of VDR  by bringing it to the "closed" position thus rendering 
the nuclear receptor to interact with coactivator through their NR boxes42. 
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2. These co activators are attracted towards the helix    3,5,12 of liganded 
VDR which  in turn allosterically stabilizes VDR-RXR heterodimer on 
VDRE and aid in triggering strong  heterodimerization46. 
3. Hence VDR LBD is migrated towards the 5’side of RXR LBD and in 
doing so  RXR LBD  is rotated to 180˚ by the driving forces of ionic and 
hydrophobic interactions between 9 and 10  helices of VDR and 
consequent helices of RXR. 
4. 1, 25(OH)2 D mediated gene transcription the events like ligand intensified 
heterodimerization, VDRE docking, and coactivator recruitment by VDR  
appears to occur always  together and are not separable 
5. These conformational changes allosterically elicited in VDR by the 
interactions with ligand, RXR and DNA have the extra  effect of 
converting VDR into more capable  substrate for one or more serine 
protein kinases.  
6. The most prominent phosphorylation is catalyzed by casein kinase II on 
VDR serine 208. This event potentiate  the transcriptional activity of 
RXR-VDR heterodimer possible by enhancing interaction with 
coactivators DRIP 205. 
7. The liganding of VDR conformationally influences its RXR heteropartner 
and  cause the AF-2 region of RXR to rotate into the closed or active 
position. 
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8. Now RXR have the potential to bind additional coactivator and serve as a 
subordinate partner where VDR is the primary receptor within the 
heterodimer. Hence RXR on heterodimerization with VDR cannot  bind 9-
cis retinoic acid46. 
LIGAND DEPENDENT REPRESSION: 
1. One of the mechanisms of repression is recruitment of co repressors in the 
vicinity of target gene. This is done  by altering the chromatin architecture 
which is catalyzed by acetone deacetylases and methylases towards the 
receptor tethered corepressors. 
2.  The initial targeting of repressed gene is hypothesized by docking of 
liganded VDR-RXR on negative VDRE. 
3.  In case of repression the liganded VDR is conformed such that it binds to 
co repressor rather than co activator. 
4.  Non consensus nucleotides in negative VDRE occur in either or both half 
elements, such base pair changes may be adequate to drive RXRVDR into 
reverse polarity on negative VDRE. So that the corepressor is recruited to 
the helices 3 to 6 
5.  VDR undergo modification by protein phosphatases which yet again 
favor for co repressor attraction. 
6. VDR-RXR heterodimers on interaction with VDIR at the E- box of 
negative VDRE comprising CANNTG –like motif. These interactions 
promote co regulator switching so that co activators p300 is disassociated 
and co repressors like histone deacetylator gets associated resulting in 
transrepression. 
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7. Other mechanism involves WINAC (Williams syndrome transcription 
factor including nucleosome assembly complex) induces transrepression 
by interacting with ATP dependent chromatin remodeling complex  and 
VDR induced DNA methylation. 
8. Epigenetic mechanism is also involved in negative regulation of VDR. 
Example 1α hydroxylase gene is repressed by FGF-23 and1, 25(OH) 2 D, 
while the latter regulated by epigenetic demethylation. 
9. An emerging mechanism for control of gene expression is modulation by 
specific micro RNAs.26 
VDR mediated non-genomic responses: 
1, 25(OH) 2 D by its strong non covalent binding to its cognate receptor 
also elicit rapid response in target cells. Non-genomic signaling is rapid, and 
responses are generated within 1-2 min to 15 to 45 minutes rather than 
genomic takes hours to days to be apparent fully.  It may indirectly affect 
transcription by cross-talk with other signaling pathway. It involves a non-
classical membrane receptor for 1,25(OH)2D called 1,25D3-MARRS 
(membrane-associated, rapid response steroid-binding). 
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Fig.6 VDR MEDIATED GENOMIC EFFECTS 
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Non genomic actions induce36 : 
Ø  Calcium is translocated across the mucosal membrane of intestine 
Ø  Second messengers like phospholipase C, protein kinase C(PKC), G-
protein coupled receptor or phosphotidylinositol3kinase(PI3K) are 
activated when 1,25(OH)2D is bound to the plasma membrane 
Ø Activation of those second messengers causes voltage gated calcium or 
chloride channels to be opened. 
Ø  RAF/MAPK, is also a second messenger that may modulate by cross-talk 
with the nucleus for regulation of gene expression . 
Ø  Transcriptional activity of VDR is improved by ERK. 
Ø PKC stabilize VDR via phosphorylation . 
In various cell types, rapid  responses can be mediated by 1,25-(OH)2 
D acting through a population of classical VDR molecules acting outside the 
cell nucleus, associated  with caveolae of plasma membrane46. 
            VDR with ligand of its shape planar, localized in the caveolae of 
plasma membrane activates signal transduction pathway which generate rapid 
responses like generation of calcium or secretion of insulin via PKC or MAP 
Kinase to get activated  by which chloride or calcium channels  get opened or 
exocytosis. 
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Fig.7 : NON GENOMIC EFFECTS 
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When the genomic pocket of 1, 25(OH)2D is occupied by bowl shaped 
ligand VDR interacts with RR to for heterodimer that binds to VDREs in the 
region of genes controlled directly by 1,25(OH)2D. By recruiting coactivators 
or co repressors VDR-RXR-DNA modulate transcription of genes encoding 
proteins that exhibit genomic functions of vitamin D. 
Overview of polymorphism: 
It is of great interest in genetic studies which provides the opportunities 
to link molecular insights with the epidemiological data. Variations in the 
sequence of DNA or gene which occur in at least 1% of population is termed 
as “polymorphisms”. It  produces modest and subtle effects49. 
The aim of   studying polymorphism is to explain the risk of common   
disease because of   its abundance in human genome and high frequency in 
human population. The cellular effects are due to alteration in gene 
transcription, post translational or post transcriptional activity or change in the 
structure of gene product29. 
In coding or noncoding regions of a specific gene, there may be either 
a single base pair substitution of one nucleotide (SNPs) for another or a 
variable number of repeats of a short repetitive DNA sequence (VNTR). 
These variations may influence the rate of gene transcription, the stability of 
the messenger RNA or the quantity and activity of the resulting protein. 
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Significance behind SNPs: 
           Average occurrence of SNPs in DNA is 1/300 nucleotides. They act as 
biological markers to locate the candidate gene involved in the disease. By 
means of SNPs we can trace the disease that  run through the families. 
VDR GENE: (rs 731236) 
           VDR is encoded by a large gene located on the chromosome 12q12-14. 
The gene is comprised of eleven exons together with the intervening introns 
spans approximately 75 Kb. The non coding 5’end of gene comprises 3 exons 
(Type1A, 1B,1C) . Eight exons(2-8)encode the structural portion of gene. 
VDR gene encompasses two promoter regions, eight protein-coding exons 
(namely 2-9) and six untranslated exons (1a-1f). It has an extensive promoter 
region capable of generating multiple tissue-specific transcripts29. 
HGNC approved Gene symbol:  VDR 
Alternative names : 1, 25 Dihydroxy vitamin D3 receptor 
                                    Vitamin  D hormone receptor. 
Taxonomy ID : 9606(NCBI) 
Gene ID     : 7421 
Common Name : Homosapiens( Humans) 
Gene Type  : protein coding 
Rank   : species 
Authority   : Homo sapiens Linnaeus, 1758 
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Ensembl cytogenic band : 12q 13.11 
Entrez gene cytogenic band : 12q 12- q14 
HGNC cytogenic band  : 12q12-q14 
Exon count    : 11 
Annotation release (current) : 107 
 (previous) : 105 
 
 
 
 
 
 
 
 
VDR GENE POLYMORPHISM: 
Numerous polymorphisms have been identified in the VDR gene in the 
recently conducted studies. VDR gene polymorphism occur biologically in 
human population with significant differences between races and ethnic 
groups9.  
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More than sixty VDR polymorphisms have been discovered till date 
and they are present in the promoter region, in and around exons and in the 
3’UTR ( untranslated  region). This would affect the expression of gene. Any 
change in 5’ promoter region of VDR gene affect expression of m-RNA, 
change in exons affect the protein sequence, while 3’UTR affect the stability 
of m-RNA and efficiency of translation of proteins. 
On enzyme digestion DNA fragments of various length are produced 
and they can be detected by electrophoresis. This is called as Restriction 
Fragment Length Polymorphisms (RFLP) 30. 
Allelic variants of VDR gene recognized by restriction enzymes are: 
Ø Apa1 (allele A/a), 
Ø Bsm1( allele B/b )  
Ø Taq1(allele T/t) ,  
Ø Fok 1(allele F/f).  
A T/C nucleotide substitution (ATT to ATC) leading to a synonymous 
change is the Taq1 polymorphism which occurs in exon IX. A T/C transition 
polymorphism (ATG to ACG) is the Fok1 polymorphism in exon2. BsmI and 
ApaI are the Restriction site polymorphisms occur in the intron separating 
exons VIII and IX. The other polymorphism  have been reported are Tru91 in 
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intron VIII,  EcoRV  located  between  exons 8 and 9 , Cdx2 in the promoter 
region and poly(A) mononucleotide repeat in 3’ UTR61. 
 The association of certain polymorphism with the phenotype does not 
mean that the polymorphism is causing it. The co-occurrence of alleles of 
adjacent polymorphisms is called as linkage disequilibrium (LD). In effect the 
presence of one type of polymorphism can serve as an indication of the 
presence of another polymorphism linked to it.  
A polymorphism in 3’ UTR regions of VDR gene   appear to be in 
linkage disequilibrium and the allele frequency vary among the populations. 
A strong degree of LD has been found among Taq1, BsmI, EcoRV and ApaI 
RFLPs30. LD is also present between Taq1 and Poly (A) since they occur in 
similar ratios among various ethnic groups. The presence of Taq1 ‘T’ allele in 
Asians is (8%) compared to Caucasians (43%) and Africans (31%) and 
similar results for PolyA. 
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Fig.8 STRUCTURE OF VDR GENE 
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MATERIALS AND METHODS 
AIM OF THE STUDY: 
Ø To determine the frequency of TaqI vitamin D receptor gene 
polymorphism in normal individuals. 
Ø To determine the frequency of Taq1 vitamin D receptor gene 
polymorphism in normal individuals and its association with 25-hydroxy 
vitamin D levels.  
Ø To correlate the values of 25-hydroxy vitamin D levels with the levels of 
parathyroid hormone, Calcium (Total and Ionized) and Phosphorus.  
MATERIALS AND METHODS: 
This study was carried out during the period December 2014 - 
August2015.  It is a cross sectional study. The study population comprised of 
normal individuals coming for master health check up Kilpauk Medical 
College Hospital, Chennai. All procedures concerning human subjects or 
patients were permitted by the Institutional Ethical Committee. 
STUDY POPULATION: 
INCLUSION CRITERIA: Healthy unrelated individuals of age 25-60yrs 
EXCLUSION CRITERIA : Persons with diabetes.                                                                        
Persons with hypertension, Coronary artery 
disease. 
                                                       Known alcoholic, smokers etc. 
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SAMPLE COLLECTION:  
For the study, 6 ml of 12 hours Fasting Venous Blood was collected 
under sterile conditions from the antecubital vein with explicit informed 
consent.                             
I. 2ml of blood was collected in plain vials and serum was separated after   
centrifugation at 3000 rpm for 10 minutes and aliquoted, into an 
eppendorfs and stored at -20°C and were not thawed until the batch 
was analyzed for total calcium, phosphorus , total protein and albumin. 
Before storage ionized calcium is estimated. 
II. 2 ml of blood collected in  EDTA tube for DNA extraction.  Plasma 
was separated after centrifugation at 3000 rpm for 10 minutes and 
aliquoted, into an eppendorfs and stored at -20°C and were not thawed 
until the batch was analyzed for glucose, urea and creatinine. 
III. 2ml of blood collected in plain serum tube for analysis of 25-OH 
vitamin D and PTH ASSAY. 
ESTIMATION OF GLUCOSE:  
Method:  Glucose oxidase   peroxidase (GOD/POD) (End Point) 
Kit Used: Erba 
Principle 
    Glucose oxidase 
Glucose + O2 + H2O                               Gluconic acid   +   H2O 
        peroxidase 
H2O2 + Phenol+4AAP                                 Quinoneimine dye   +   H20 
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             The intensity of pink colored Quinoneimine dye is proportionate to 
glucose concentration and was measured at 505nm. 
Reagent Composition 
Reagent 1:         Enzyme reagent 
Glucose oxidase → ≥ 20000U/L 
Peroxidase  → ≥ 2000U/L 
Phenol  → 10 mmol/L 
Phosphate buffer    → 200 mmol/L 
Glucose standard    → 100 mg/dl 
Procedure 
To 1ml of working solution, 10μl of plasma was added  and Incubated   
at 37°c for 15 minutes and absorbance was measured at 505 nm. 
Reference range 
Fasting plasma glucose: 70 –100 mg/dl  
ESTIMATION OF BLOOD UREA 
KIT :  Accucare 
Method : UV - GLDH 
Principle : The test is performed as a kinetic assay in which the initial rate of 
the reaction is linear for a limited period of time. Urea is hydrolysed by urease 
to NH3 and CO2. The NH3 produced combines with alpha-oxoglutarate and 
NADH in the occurrence of glutamate dehydrogenase to produce glutamate 
and NAD. 
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Urease 
Urea  +    H2O                                        2NH4 + CO2 
   GLDH 
NH4++ NADH + H+ + 2- oxoglutarate                            Glutamate + NAD+ 
The initial rate of decrease in absorbance is directly proportional to the 
urea concentration in the sample. Absorbance is measured at 340nm. 
Reagent 
Reagent I  : buffer reagent 
Reagent II  : enzyme reagent 
Urea standard : 50 mg/dl 
Mix 4 parts (4 ml) of buffer reagent with one part (1 ml) of enzyme reagent 
and mix gently. 
Procedure 
To 1 ml of the reconstituted reagent 10μl of plasma is added and   
absorbance measured immediately at 340 nm. 
Reference Range 
Serum/ plasma Urea   →   15- 40 mg/dl 
ESTIMATION OF SERUM CREATININE 
Kit used  :  ERBA 
METHOD   : Jaffe's Method   , Initial rate method 
Principle :    
              Creatinine in alkaline solution reacts with picrate to form a orange-
yellow compound. The color is proportional to the concentration of creatinine 
in the sample when measured at 505nm. 
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Reagent composition: 
Reagent I   :  Picric acid reagent. 
Picric acid  – 25.8  mmol/L 
  Reagent   II:  Sodium hydroxide reagent. 
Sodium hydroxide  – 95 mmol/L 
Creatinine standard:     2 mg/dl 
 Reagents were allowed to attain room temperature. Equal volumes of  
reagent 1 and reagent 2 were mixed , waited for 15 minutes before use . 
Procedure 
To 1 ml of the reconstituted reagent 100μl of the plasma was added 
and absorbance (A1 ) at 20 seconds after mixing was noted & final 
absorbance ((A2 ) at 80 seconds were measured. 
Calculation 
A = A2 - A1 
Absorbance  of Test X concentration of standard (mg/dl) 
Creatinine (mg/dl) =  
A   of standard 
 
 Reference Range: 
Males  : 0.7 - 1.4 mg/dl 
Females : 0.6 - 1.2mg/dl 
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ESTIMATION OF SERUM CALCIUM: 
KIT:  SPINREACT 
METHOD: ArsenazoIII. 
PRINCIPLE: Calcium with ArsenazoIII (1,8–DiHydroxy-3,6-disulpho-
2,7naphthalene-bis(azo)-dibenzearsonic acid), at neutral pH, yields a blue 
colored complex. The intensity of the color is directly proportional to the 
calcium concentration in the sample. 
REAGENTS: 
R   -   IMIDAZOLE BUFFER PH 6.5 →   100mmol/L 
Arsenazo III        →                          120mmol/L 
 Standard   -       10 mg/dl 
PROCEDURE: 
To 1 ml of the reagent 10μl of serum added. Mix and incubate for  
2 min at 37˚C and reading was taken at 650 nm. 
REFERENCE RANGE: 
Serum/ plasma:   8.5-10.5mg/dl 
ESTIMATION OF PHOSPHORUS: 
KIT:  SPINREACT 
METHOD: PHOSPHOMOLYBDATE.UV 
PRINCIPLE: 
Inorganic phosphate reacts in acid medium with ammonium molybdate 
to form a phosphomolybdate complex with yellow color. The intensity of the 
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color is directly proportional to the inorganic phosphorus concentration in the 
sample. 
REAGENTS:     
   R -   Ammonium molybdate   -à 0.40 mM 
           Sulphuric acid à  210Mm 
            Detergents. 
 Standard  -     5mg/dl 
PROCEDURE: To 1ml of the reagent 10μl of serum added. Mix and 
incubate for 5 minutes and reading taken at 340 nm. 
REFERENCE VALUE: 
Serum or Plasma-   2.5-5.0 mg/dl 
ESTIMATION OF ALBUMIN: 
KIT:     PRIETEST 
METHOD: Bromocresol green, End point 
PRINCIPLE: 
   Serum albumin in the presence of bromo cresol green at a slightly acid ph 
produces colour change of the indicator from yellow-green to green blue. 
   Albumin    +    BCG --------------à  Albumin-BCG complex. 
REAGENT:    
Succinate buffer →   75mmol/L 
Bromo cresol green→ 0.15mmol/L 
Standard:   4.0 g/dl 
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PROCEDURE: 
To 1 ml of the reagent 10μl of serum added. Mix and incubate for 5 
minutes and reading taken at 620 nm. 
REFERENCE RANGE:    3.5 – 5.2 g / dl.  
ESTIMATION OF TOTAL PROTEIN: 
 KIT:  ACCUCARE 
METHOD:  BIURET   , End point 
PRINCIPLE: 
          Proteins give intensive violet blue colored complex with copper salt in 
a alkaline medium, iodide is included as a antioxidant . The intensity of the 
color is directly proportional to the concentration of protein in the sample. 
REAGENT  :  Biuret reagent  
Standard:    6g/dl 
PROCEDURE: 
         To 1 ml of the reagent 20μl of serum added. Mix and incubate for 10 
minutes and reading taken at 540 nm. 
REFERENCE RANGE: 
Serum/ plasma:   6.6 to   8.3 g/dl. 
ESTIMATION OF IONIZED CALCIUM: 
Serum ionized calcium measured by Ion selective electrodes by Eletrolyte 
analyser 9180 (ROCHE) 
Reference range: 1.15 to 1.33mmol/dl 
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 ESTIMATION OF 25-OH VITAMIN D LEVELS: 
25-OH vitamin D in serum is determined using ADVIA 
CENTAUR vitamin D assay on ADVIA CENTAUR XP systems. 
METHOD: CLIA 
PRINCIPLE: 
The ADVIA Centaur VitD assay is an 18-minute antibody competitive 
immunoassay that uses an anti-fluorescein monoclonal mouse antibody 
covalently bound to paramagnetic particles (PMP), an anti-25(OH)vitamin D 
monoclonal mouse antibody labeled with acridinium ester (AE), and a 
vitamin D analog labeled with fluorescein.  
An inverse relationship exists between the amount of vitamin D 
present in the patient sample and the amount of relative light units (RLUs) 
detected by the system.  
REFERENCE RANGE: 
VIT D:     10 – 30 ng/ml 
ESTIMATION OF INTACT PTH ASSAY: 
Determination of intact parathyroid hormone in serum using ADVIA 
CENTAUR i PTH assay on ADVIA CENTAUR XP systems. 
METHOD: CLIA  
PRINCIPLE: 
The ADVIA Centaur Intact PTH assay is a two-site sandwich 
immunoassay uses direct chemiluminometric technology. It  uses constant 
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amounts of two anti-human PTH antibodies in the Lite Reagent. The 
polyclonal goat anti-human PTH (N-terminal 1-34) antibody labeled with 
acridinium ester is the first antibody. The biotinylated polyclonal goat anti-
human PTH (39-84 regions) antibody is the second antibody. Streptavidin in 
the solid phase is covalently coupled to paramagnetic latex particles. 
REFERENCE RANGE:   11.1 -79.5pg/ml 
For gene polymorphism studies fasting blood was collected in 2 ml EDTA 
coated tube. 
I. DNA EXTRACTION BY KIT METHOD: 
The Mag pure human blood genomic DNA Preparation kit: From Helini 
Biomolecules,   Chennai. 
PRINCIPLE: 
RBCs and cells are incubated with proteinase K in the presence of 
chatropic salt, which immediately inactivates all nucleases. Following 
addition of magnetic beads and binding buffer , precipitated cellular nucleic 
acids selectively bind to magnetic beads. Bound nucleic acid is purified in a 
series of rapid wash steps to remove contaminating cellular components. 
Finally low salt elution releases the nucleic acids from the magnetic beads. 
This sample method eliminates the need for organic solvent extractions, 
allowing for rapid purification of many samples simultaneously. 
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COMPONENTS OF THE KIT: 
· Proteinase K 
· Lysis Buffer 
· Binding Buffer 
· Wash Buffer-1 
· Wash Buffer-2 
· Elution Buffer 
· Magnetic beads 
         Proteinase K stored at -20˚C 
          Mag Pure Magnetic Beads at 4˚C 
          Buffers  at  room temperature. 
PROCEDURE FOR DNA EXTRACTION: 
PRE-PROCEDURE STEPS: 
§ Set water bath at 70˚C 
§ Label five 2ml micro centrifuge tube as Lysis, wash-1, wash-2, wash-2 
and elute. 
§  300µL of lysis buffer is added to the tube labeled as lysis and close the 
lid. 
§  500µL of wash buffer-1 and wash buffer-2 added to appropriate labeled 
tubes and close the lid. 
§ 100µL of elution buffer is added to the tube labeled as elute and close the 
lid. 
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PROCEDURE: 
Ø 0.2ml of fresh human blood or 0.1 ml of buffy coat into 2ml              
centrifuge tube labeled as lysis. Mixed well and vortexing done. 
1.  20µL of Proteinase K is added and mix well by vortexing, incubated at 
room temperature for 3 minutes. 
2.  40µl of Mag Pure Beads is added and 500µl of binding buffer 
supplemented with ethanol is added and mixed by vortexing. 
3. Using Mag stick with fresh tip MagPure beads are captured and transfer to 
wash buffer-1 and vortexed briefly. 
4.  Mag stick with tip is inserted to capture all the beads from wash buffer -1 
 and transfer to wash buffer-2. Mixed gently by vortexing 
5. Magstick with tip to capture all beads and transferred to wash buffer-2. 
mix gently by  vortexing. 
6.  Mag stick with tip is inserted to capture all beads and transfer to elute. 
Discard the tip. 
7. Resuspend the magnetic beads by brief vortexing and incubated in water 
bath at 70˚C for 5 minutes. 
8. Mag stick with fresh tip is inserted to capture Mag pure beads from the 
elution buffer and the tip is discarded. 
9.  The elute is transferred into fresh 1.5 ml tube and the purified DNA is 
used immediately or stored at-20˚C 
IDENTIFICATION 
Extracted DNA was identified by 1% agarose gel electrophoresis and 
comparison with a known molecular weight 1kb DNA (Lambda DNA)ladder 
as depicted in  
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PCR(polymerase chain reaction) was carried out in a reaction in volume of 
50µL with the following components in the following manner: 
Red Dye PCR master mix – 25µL 
Red Dye PCR master mix – 25µL 
Primer mix – 10.0 µL 
DNA– 5.0µL 
Distilled water- 10µl 
Total volume: 50µl 
POLYMERASE CHAIN REACTION (PCR) 
Amplification of the extracted DNA was carried out in CYBERLAB 
SMART PCR-PRO, thermal cycler with the following cycling conditions. 
STEPS IN PCR TAQ1 POLYMORPHIC SITE: 
v Initial denaturation - 95° C /4min 
34cycles of 
Ø Cycle Denaturation  at 95°C for  30 seconds 
Ø Cycle Annealing  at 58°C  for 30 seconds 
Ø Cycle Extension at 72°C  for 45 seconds 
Ø Final Extension at 72°C for 5min 
Amplified product – amplicons of 600 bp was identified by 2.5% 
agarose gel electrophoresis by comparison with a known 100bp DNA ladder 
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AGAROSE GEL ELECTROPHORESIS 
•  PCR product is run on 2.5% agarose gel in a 25 mL agarose cast as 
follows: 0.625g of agarose is weighed and dissolved in 25 mL of TAE 
buffer with a pH of 8.0. 
•  It was microwaved for 60 secs, cooled and ethidium bromide  0.5 
µg/ml was added. It is poured into a cast and allowed  to solidify for 45 
min before it is kept in the electrophoresis tank. 
•  10µL of PCR product is loaded onto wells and 4µL of 100bp DNA 
ladder is loaded onto single well as a marker. It is run in 
electrophoresis tank for  30min and visualized under UV illumination 
in e gel imager from life technologies . 
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FIG :10     PCR PRODUCT- rs731236 
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RESTRICTION DIGESTION OF THE PCR PRODUCTS  TAQ1 SITE 
RESTRICTION FRAGMENT LEGTH POLYMORPHISM 
Taq1gene polymorphism at the site was spotted by digestion of the 
amplified PCR product with the TaqI restriction enzyme trailed by run in 
2.5% agarose gel electrophoresis. 
Restriction Digestion Procedure 
Taq1 buffer  – 5 µL   
Taq I  enzyme  – 2.5 µL 
PCR   Product – 30.0 µL 
Distilled  water – 12.5 µL 
 ------------------ 
Total    50.0 µL 
------------------ 
 
The entire procedure is carried out in ice. The contents are mixed thoroughly. 
· The eppendorf is then placed in a 65°C waterbath for 30minutes 
· Restriction digested product is subjected to 2.5% agarosegel 
electrophoresis for genotyping. 
Two restriction sites for Taq I  with   in  600 bp 
t ALLELE-   have restriction site  
T ALLELE- absence of restriction site 
v tt (homozygous individuals)- will yield 400bp,200bp 
v Tt (heterozygous individuals)- will yield 600, 400bp,200bp 
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v TT(homozygous individuals)- will yield 600bp 
RESTRICTION DIGESTED PRODUCT VIEWED BY RUNNING IN  
2.5% AGAROSE GEL ELECTROPHORESIS 
PROCEDURE: 
•  Restriction Digestion product is run on 2.5% agarose gel in a 25mL 
agarose cast as follows: 0.625g of agarose is weighed and dissolved in 
25mL of TAE buffer with a pH of 8.0. 
•  It is microwaved for 60 secs, cooled and Ethidium bromide 
concentration 0.5 µg/ml  from the stock of 10mg/mL is added. It is 
poured into a cast and allowed to solidify for 45 min before it is kept in 
the electrophoresis tank. 
•  20µL of Restriction Digestion product is loaded onto wells and 4µL of 
100bp DNA ladder is loaded onto single well as a marker. It is run in 
electrophoresis tank for 45min and visualized under UV illumination in 
E gel imager from life technologies (Fig.)Analysis was done using 100 
bp and 50 bp ladder 
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FIG.11  RESTRICTION DIGESTION PRODUCT- rs731236 
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RESULTS 
TABLE-1 Shows age, glucose, urea and creatinine among study 
population: 
Variable Number Mean Std.dev 
Age 100 38.2800 10.07154 
Glucose 100 62.6000 22.96506 
Urea 100 19.8200 6.08090 
Creatinine 100 .8300 0.17321 
 
This table shows the routine parameters (glucose, urea, 
creatinine)within the study population. And these parameters are within 
normal limits. 
Table-2   Distribution of vitamin D levels in the study population. 
Vit D 
Group-1 
(<10ng/ml) 
Group-2 
(10-20ng/ml) 
Group-3 
(>20ng/ml) 
Numbers(n) 21 (21%) 43 (43%) 36 (36%) 
Mean 6.947 14.31 30.392 
Std dev 1.914 2.657 8.085 
 
Based on the vitamin D levels the study population are grouped into three 
groups. 
Group-1 --- <10ng/ml ( vit D deficiency) 
Group-2 ---- 10-20ng/ml ( vit D insufficiency) 
Group-3 --- >20ng/ml (vit D sufficiency) 
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Among the study population about 21% of individuals are vitamin D deficient 
(group- and 43% individuals are vitamin D insufficient(group-2) and 36% of 
the population are  vitamin D sufficient(group-3)  
Table-3 Correlation of vitamin D with parathyroid hormone among the 
study population 
 
Vit D 
(ng/ml) 
N Mean Std dev p value 
PTH 
<10 21 68.3143 39.5684 
0.002*** 10-20 43 50.0070 25.3879 
>20 36 41.9211 16.9526 
 
Table- 3 shows correlation between vitamin D levels and parathyroid 
hormone. 
 A significant inverse relation was observed between vitamin D and 
intact parathyroid hormone levels in all the three groups. As vitamin D level 
decreases there is a  proportionate increase in parathormone level and is found 
to be statistically significant with a   p value of 0.002.   
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FIG.12  CORRELATION OF VIT.D  AND PTH  
AMONG STUDY POPULATION 
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Table -4  Correlation of vitamin D with total calcium, ionized calcium, 
phosphorus. 
 Vit D N MEAN STD DEV p value 
Total 
calcium 
<10 21 8.146 1.03277 
< 0.001 10-20 43 9.2047 1.72157 
>20 36 11.1778 1.09938 
I.calcium 
 
<10 21 1.1048 0.08664 
0.887 10-20 43 1.1186 0.15001 
>20 36 1.1056 0.13927 
Phosphorus 
<10 21 3.6810 0.80164 
0.337 10-20 43 3.4605 0.57782 
>20 36 3.4583 0.50787 
 
The total calcium    In group 1 ----7.2- 9.2 mg/dl  
In group 2 --- 7.5 – 10.9 mg/dl  
                               In group 3 --- 10.1 -12.1mg/dl 
In group 1 the total calcium level is decreased which is statistically 
significant with a  p value <0.001. In group-2 and group-3 the total calcium is 
within normal limits and it is  statistically insignificant. 
The ionized calcium and phosphorus are found to be in normal range in 
all the three groups and it is also statistically insignificant with the p value  
0.887 and 0.337 respectively. 
                            . 
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FIG.13 CORRELATION OF VIT D AND TOTAL CALCIUM 
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Table -5 Genotype frequency distribution of taq1 gene in study 
population 
 
Genotype Frequency Percent 
tt 94 94.0 
Tt 6 6.0 
Total 100 100.0 
 
          This table   shows the genotype distribution among the study population 
of which the common genotype is homozygous tt genotype which accounts 
for (94%) and the heterozygous Tt genotype accounts for (6%). There is no 
homozygous TT genotype in our study population. 
Table-6: Correlation between the genotype and vitamin D level in study 
population: 
Genotype 
Group1 
N   (%) 
Group2 
N    (%) 
Group3 
N  (%) 
Total 
N  (%) 
p value 
Tt 21 (22.3%) 39 (41.5%) 34 (36.2%) 94 (100%) 
0.49 
Tt 0   (0%) 4  (66.7) 2 (33.3%) 6   (100%) 
 
This shows among the study population, the group-1 individuals have 
increased frequency of tt genotype of (22.3%) whereas the group-2 
individuals have increased frequency of Tt   genotype of (66.7%) 
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FIG.14 PIE CHART SHOWING GENOTYPE DISTRIBUTION 
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DISCUSSION 
The present study is an attempt to evaluate the normal distribution of 
Taq1 gene polymorphism in unrelated normal healthy individuals in Chennai 
population. 
The genes encoding VDR is located on chromosome 12, and consists 
of 14 exons which span approximately 75 kilo bases of genomic DNA67. In 
the VDR gene many polymorphisms have been discovered so far and their 
functional significance and probable effects on disease vulnerability are under 
trial (zumuda et all). 
Of several allelic variants in the VDR gene, one which is present in 
3’UTR is Taq1 gene polymorphism. It is a T/C nucleotide substitution (ATT 
to ATC) leading to a silent change at codon 352 both coding for isoleucine 
and is in linkage disequilibrium with other variants28. 
This polymorphic site reference ID number is rs73123648. Taq1 gene 
polymorphism is studied in most diseases like cancer, osteoporosis66, 
urolithiasis, Type1 DM64, obesity and coronary artery disease69. 
The possible functional mechanism attributed to polymorphism in  
3’ UTR include change in VDR gene expression by altering polyadenylation, 
localization of mRNA, stability of mRNA, and translational efficiency. The 
stability of mRNA influences gene expression by affecting the amount of 
mRNA available to be translated and the probable means are: 
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1. The miRNAs (micro –RNAs)can inhibit both initiation step of translation 
and steps after that  such as premature termination. Many mRNAs have 
multiple binding sites for miRNA and translation is most efficiently 
inhibited when multiple miRNAS are bound to the mRNA. 
2. Length of 3’ UTR is considerable , since  3’ UTRs which are longer are 
associated with decreased levels of gene expression because they contain 
more miRNA and protein binding sites that are involved  translation 
inhibition. 
3. Many 3’ UTR has AU rich elements (ARES). Proteins binding to ARES, 
stability  is affected or decay rate of transcripts in a localized manner or 
affect initiation of translation. 
4. 3’ UTR contains the sequence AAUAAA which favors  several hundred 
adenine residues called poly (A) tail to  be added to the end of mRNA 
transcript. Poly (A) binding protein (PABP) on binding  to this tail 
contributes regulation of mRNA translation and stability.  
5. Some mi RNAs cause suppression of transcription by binding to the   
complementary sequences in DNA and  by attracting the enzymes which 
directly methylate the DNA70. 
Yug Fang et al identified difference in VDR mRNA expression level 
and stability between hap1 and hap2 alleles  across  3’ UTR. The fracture risk 
hap1 allele causes 15% lower levels of mRNA expression than hap2 in all 
tested cell lines. This is in line with 30% faster decay or lower stability of 
VDR mRNA observed in osteoblast cell line74. 
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         In view of this, a population based study was performed in Chennai 
population to address the following questions: 
1. To find the prevalence of vitamin D deficiency among the study 
population. 
2. To find the frequency of VDR Taq1genotype distribution in the study 
population. 
3. Is VDR gene polymorphism is the cause for differences in the vitamin D 
status among the study population? 
Among the study population about 21% are found to be vitamin D 
deficient(<10ng/ml), 43% are vitamin D insufficient(10-20ng/ml) and 36% 
are vitamin D sufficient(>20ng/ml)  
Correlation between vitamin D levels and parathyroid hormone, total 
calcium and ionized calcium were done in our study population and the 
results are as follows: 
In this study the vitamin D levels have negative correlation with intact 
parathormone levels. As vitamin D level decreases there is a proportionate 
increase in parathormone level.  
The total calcium level was decreased in vitamin D deficiency 
individuals (<10ng/ml), whereas it was within normal range in other two 
groups. 
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Zuberi LM Habib A et al stated in their study, calcium level is 
decreased only  in severe vitamin D deficiency  but it is normal in moderate 
and mild vitamin D deficiency which is similar to our study. 
Mansoor.S.Habib et al described that about 30% of asymptomatic adults with 
vitamin D deficieny and secondary hyperparathyroidism have normal levels 
of calcium 83. 
Ionized calcium was within normal range in all the individuals of study 
population. In vitamin D deficiency, plasma calcium is maintained at the 
expense of bone calcium but persistence of deficiency leads to fall in calcium 
levels and secondary hyperparathyroidism81. Singh et all reported that there 
exist a poor correlation between vitamin d deficiency and ionized calcium, so 
that vitamin D deficiency cannot be predicted by ionized calcium84. 
Serum phosphorus levels are within normal limits and it does not 
correlate with vitamin D levels in this study similar to the study conducted in 
Karachi.(Shaheen et al,2012) revealed  30 to 40 % of calcium absorption in 
intestine is increased by vitamin D  and phosphorus absorption by 80%. 
Vitamin D deficiency leads to secondary hyperparathyroidism which results 
in loss of phosphorus in urine and decrease the intestinal absorption of 
phosphorus. This results in low or   low normal phosphorus concentration85.  
The second hypothesis of our study about the distribution of genotype 
is as follows: the distribution of tt genotype is significantly higher among the 
study population. In this study population, we found 94%  of tt genotype, 6% 
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of Tt genotype and  the homozygous TT genotype was not found The 
presence ofTaq1  T  allele in Asians is (8%) compared to Caucasians (43%) 
and Africans (31%) as stated in Kim Kostner et al48.  
In this study the frequency of T allele is 6%. The finding of this study 
is similar to a study done in Austria (Ewald et al) where the frequency of tt 
genotype was found higher than TT genotype8 
The genotype distribution in this study is not similar compared to the 
studies done so far in Japan (Tokita et al,1996), in china(kung et al 1996), 
American black Pennsylvania (zumuda et al, 1997), North India  
(Hemant K Bid et al 2005) 
 The genotype distribution was not found to be in agreement with 
Hardy Weinberg equilibrium in our study.  Zumuda et al in his study 
describes that distribution of VDR genotypes was not in Hardy Weinberg 
equilibrium, the reason behind this may be, apart from genotyping errors, 
there may be fluctuations due to small samples, nonrandom mating, and 
migration into or out of the population, selective survivorship among 
genotypes, population stratification, and admixture of different ethnic 
groups67. 
Hemant k bid et al in their studies says that there was a lack of data 
regarding the allelic variations in taq1 genotype from Indian subcontinent 
where population ethnicities are quite common6.      
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The third hypothesis which focuses influence of polymorphism on the 
vitamin D status showed that Taq1 polymorphism does not influence vitamin 
D status. 
Further attempt should be mandatory in order to understand the 
molecular and cellular variations affected by the polymorphism and to 
execute observational studies in larger populations. Study of different 
haplotypes, instead of SNPs could reduce the inconsistencies found so far, 
until then the role of VDR polymorphism will still be a topic for debate. 
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CONCLUSION 
Ø From this study we conclude that the predominant VDR Taq1 
genotype in Chennai population is tt genotype. . 
Ø Also the homozygous genotype (TT) was not obtained in our study 
population. 
Ø About 21% of individuals are vitamin D deficient.  
Ø When genotypes are analysed with respect to 25(OH)D ,no correlation 
was observed with Taq1 SNP. 
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LIMITATIONS 
Limitations of this study are: 
Ø Small sample size. 
Ø Probable occurrence of linkage disequilibrium of Taq1 gene with other 
genes like Bsm1, Apa1 in the 3’ UTR. 
Ø Difference in race, diet, or latitude may modify the influence of 
polymorphisms on propensity of disease, diluting the effects observed 
in other population. 
Ø Study of different haplotypes instead of SNPs would help in clarifying 
the molecular mechanism underlying the associations observed in 
3’UTR polymorphisms 
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SCOPE FOR FURTHER STUDY 
Ø More studies with large samples are needed to confirm the genotype 
distribution in the study population. 
Ø Probable occurrence of linkage disequilibrium of Taq1 gene with other 
VDR genes like APA1, BSM1 in 3’ UTR site has to be established. 
Ø Whole genome sequence analysis is needed to reveal extensive level of 
variation and heterogeneity between individuals and populations and 
genome-wide association studies (GWAS) has to be done , as these 
analysis eliminates bias in the selection of the candidate genes. 
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ANNEXURE 
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ABBREVIATIONS: 
VDD  – Vitamin D Deficiency 
VDR   – Vitamin D Receptor 
VDRE  – Vitamin D Response Element 
RFLP   – Restriction Fragment Length Polymorphism 
25-(OH) D  – 25-Hydroxy Vitamin D 
1, 25(OH)2 D – 1,25 Di Hydroxy Vitamin D 
PTH   – Parathyroid Hormone 
DBP   – Vitamin D Binding Protein 
SZA   – Solar Zenith Angle 
TRPV  - Transient Receptor Potential Vanniloid 
OPG   –  Osteoprotegrin 
DM   – Diabetes mellitus 
RXR   – Retinoid X Receptor 
VDIR   – VDR Interacting Repressor 
CTE   – C -Terminal Extension 
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DBD   – DNA Binding Domain 
LBD   - Ligand Binding Domain 
nVDRE  – Negative vitamin D response Elements 
HAT   – Histone Acetyl Transferase 
SRC   – Steroid Receptor Coactivator 
SNPs   – Single Nucleotide Polymorphisms 
UTR   – Un translated Region 
miRNAs  – Micro RNAs 
PCR   – Polymerase Chain Reaction 
LD    – Linkage Disequilibrium 
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PROFORMA 
Date: 
Name:    OP/IP No:    SAMPLE ID: 
Age:     Sex          : 
Address:    Occupation:    State: 
PRESENTING COMPLAINTS: 
PAST HISTORY: 
Liver disease/Kidney disease/ DM/ Skeletal disease/ Drugs/ 
TREATMENT HISTORY: 
PREVIOUS HOSPITALIZATION: 
PERSONAL HISTORY: Smoking/ Alcohol intake. 
O/E: 
Built                                 Height-                                                     Weight- 
BMI-                                Waist-Hip-Ratio 
Pedal edema/Anemia/Clubbing /Lymphadenopathy 
VITALS:          BP:                    PulseRate: 
SYSTEMIC EXAMINATION : 
CVS:                                                                        Abdomen :    
RS :                                                                          CNS: 
99 
Diagnosis: 
Investigations: 
1. Blood glucose,urea,creatine                              
2.  25- HydroxyVitamin D levels 
3.  Intact Parathyroid hormone  
4.   Serum Phosphorus 
5. Serum Calcium(Total &Ionized) 
5. Serum Protein  
6. Serum Albumin                                                             
7.  Genotype:TT/Tt/tt 
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S.No. NAME AGE GENDER GLUCOSE UREA CREATININE T.
CALCIUM
ION. 
CALCIUM
PHOSPHORUS T.PROTEIN ALBUMIN VIT. D PTH GENOTYPE
1 LILLYMARY 42 F 72 13 0.8 8.4 1.2 3.4 8.4 3.7 5.73 20.6 tt
2 AKILABANU 27 F 72 15 0.8 9.1 1.3 3.6 6.9 3.1 4.56 33.5 tt
3 ANANDHI 25 F 56 20 0.8 7.7 1.2 4 7 4 9.53 84.9 tt
4 ILAYARAJA 26 M 44 18 0.9 9.5 1.1 2.8 7.1 4.6 12.05 43.7 tt
5 EZHIL 32 F 83 10 0.8 7.9 1.1 3.4 7.2 3.9 5.85 57.8 tt
6 GEETHA 42 F 58 19 0.8 11.1 1.2 3.1 6.7 3.9 17.46 22 tt
7 AJESH 25 M 63 16 1.1 10.6 1.2 3.5 7.9 4.3 26.21 39.2 tt
8 KALAIARASI 27 F 62 20 0.6 11.4 1.1 3.5 6 3.3 23.31 48.8 tt
9 HARIKRISHNAN 44 M 38 10 1 11.7 0.7 2.5 5.9 3.1 26.21 79.9 tt
10 NOORJAHAN 25 F 62 14 0.8 9.4 1.2 3.8 6.4 3.7 18.86 96.3 Tt
11 VANAJA 33 F 40 15 0.6 12.3 1.2 3.1 6.4 3.7 28.13 59.7 tt
12 POONGODI 34 F 76 22 1.1 12.1 1.2 3.1 7.6 3.6 30.57 17.4 tt
13 MOHANRAJ 39 M 64 15 0.9 9.4 1.1 3.5 5 3.5 15.85 42.5 tt
14 SARAVANAN 40 M 69 22 1.2 6.9 1.1 3.4 6.8 3.8 5.74 53.2 tt
15 UDAYA 36 F 55 16 0.7 7.5 1.2 3.3 7.9 3.9 9.23 116 tt
16 ABZAL 39 M 149 18 1 7.6 1.1 3.6 7.5 4.5 8.5 61 tt
17 MOWRI 34 M 56 25 1.2 5.3 0.9 4.3 7.7 4.9 10.92 60.8 tt
18 LATCHIYA 32 M 40 16 1.1 7.8 1.1 2.8 6.9 4.2 12.87 12.7 tt
19 JAYABHARATHI 42 F 73 22 0.8 10.5 1.2 4.3 6.3 4 17 28.6 tt
20 BHOOMATHI 26 F 62 14 0.7 7 1.1 2.6 5.7 4 4.67 148 tt
21 VEL 29 M 43 18 0.9 8.4 1.1 3.4 6.4 3.6 13.57 17.2 tt
22 JAGAN 26 M 40 22 1.1 7.1 1 4.4 7.9 4.9 4.95 38.3 tt
23 GANGA 43 F 62 22 0.9 8.8 1.1 3.1 4.6 3.3 13.11 83.5 tt
24 SUMATHI 42 F 80 19 0.8 9.1 1.1 3.4 7.2 4 14.31 34.8 tt
25 RAMAYEE 40 F 52 17 0.9 6.8 0.9 2.8 6.6 4.3 11.45 62 tt
26 PRABAKAR 40 M 61 25 0.7 11.3 1.1 3.4 6.2 4.2 28.13 25.2         Tt
27 SIVARANJANI 25 F 62 14 0.8 10.5 1.1 2.7 7.1 4.4 19.61 46.3 tt
28 KUMAR 30 M 53 21 1 10.3 1.1 3.9 6.9 3.8 23.4 16.6 tt
29 GOMATHI 40 F 79 31 0.9 9 0.6 3.7 7.1 4.3 17.4 43 tt
30 VENKATRAMAN 40 M 73 36 1.3 9.8 0.5 3.2 7.4 4.4 31.36 22.1 tt
31 THENMOZHI 48 F 78 21 0.8 9.1 1.2 3.9 7.2 3.2 14.04 61.1 tt
32 VIJAYA 53 F 64 13 0.6 11.4 1.1 4.1 7.7 4.3 21.22 41 tt
33 GEETHA 59 F 95 21 0.8 14.6 1.1 3.2 8.1 4.2 13.39 132 tt
34 MUTHUKUMAR 47 M 64 22 0.9 12.5 1 3.3 5.7 3.7 22.31 43.6 tt
35 AMBIGA 53 F 51 18 0.7 8.6 1.2 3.7 7.3 5.1 18.77 44.5 tt
S.No. NAME AGE GENDER GLUCOSE UREA CREATININE T.
CALCIUM
ION. 
CALCIUM
PHOSPHORUS T.PROTEIN ALBUMIN VIT. D PTH GENOTYPE
36 INDIRA 45 F 54 29 0.8 8.4 1.1 3.4 6 3.7 14.5 44.1 tt
37 ARUNDHADHI 52 F 68 21 0.8 13.8 1.1 3.6 5.9 3.4 22.04 48.1 tt
38 DURGA 27 F 60 15 0.7 8.3 1.1 3 8 4.5 11.17 50.2 tt
39 GOPALAKRISHNAN 30 M 67 20 0.9 11.3 1.1 3.5 6.6 4.4 41.62 21.7 tt
40 PONMANI 52 F 64 19 0.7 11.9 1.2 3.5 7 3.7 28.7 31.5 tt
41 DAVID 47 M 75 25 1 12.6 1.1 2.9 7.2 3.5 48.9 48.9 tt
42 SURYA 28 F 39 29 0.8 11.4 1.1 3.2 6.4 3.9 12.11 42.5 tt
43 ANURADHA 44 F 53 14 0.6 9.3 1 3.5 6.1 3.4 5.82 64.4 tt
44 RANI 58 F 59 15 0.6 11.4 1.1 3.3 9.4 4.3 4.65 41.1 tt
45 SELVI 32 F 196 22 0.8 14.4 1.1 3.5 7.6 4.6 13.87 12.7         Tt
46 THILAGA 26 F 70 22 1 9.5 1.1 4.9 6.9 3.3 7.8 20.9 tt
47 KRISHNAVENI 27 F 58 19 0.8 10 1 4 7.2 4.9 19.92 65.6 tt
48 CHELLAKANNU 58 M 66 22 0.8 8.2 0.9 3 7.3 4.9 9.47 184 tt
49 KUMARI 55 F 84 22 0.9 8.5 1.1 3.5 9.4 4.6 13.11 21.5 tt
50 SELVI 29 F 87 33 0.9 9.9 1.2 3.4 6.2 3.9 15.56 50.4 tt
51 ALAMELU 38 F 65 11 0.6 11.8 1.1 3.4 6.4 3 15.19 23.3 tt
52 AROKYA 38 F 57 21 0.8 11.7 1.2 3.3 7.9 3.8 44.4 31.7 tt
53 JAYALAKSHMI 58 F 78 23 1 12.1 1.1 3.5 7.6 3.5 49.97 32.9 tt
54 MALLIGA.B 50 F 59 33 1 9.5 1.2 3.2 6.9 4.2 18.62 46.1 tt
55 SELVARAJ 25 M 38 27 1 9.4 1.2 4.4 9.6 3.8 27.2 18.7        Tt
56 SUSEELA.B 29 F 76 26 0.9 12 1.2 3.4 7.4 3.8 25.21 36.2 tt
57 JAGAN 31 M 62 29 1 12.6 1.1 3.6 6.6 3.8 25.32 33.8 tt
58 MANGAMMA 38 F 64 27 0.9 11.9 1.2 3.7 6.3 3.3 35.95 38.5 tt
59 KOKILA 28 F 80 26 0.7 9.6 1.1 3.2 7.1 3 12.89 50.9 tt
60 BALAJI 28 M 68 32 1.1 11.3 1.1 2.7 5.3 3 23.82 62 tt
61 JOTHI 54 F 85 31 1.2 8.9 1.1 4.1 7.7 4.4 14.2 35.3       Tt
62 VENKATESAN 25 M 59 24 0.6 10.4 1.2 3.4 6.6 4.4 14.39 18 tt
63 SANTHAMARY 55 F 67 32 0.9 11 1.1 3 8.3 4.6 24.67 49.3 tt
64 MARYSUBILA 34 F 47 20 1 12.2 1.1 4.4 8.2 4.5 35.6 63 tt
65 MEERA.V 50 F 56 20 1 10.7 1.1 3.4 7.4 4.4 45.76 47.6 tt
66 SELVI.B 34 F 52 33 0.8 9.4 1.2 3 7.4 4.3 16.79 74.9 tt
S.No. NAME AGE GENDER GLUCOSE UREA CREATININE T.
CALCIUM
ION. 
CALCIUM
PHOSPHORUS T.PROTEIN ALBUMIN VIT. D PTH GENOTYPE
67 SRIMATHY 26 F 48 19 0.8 8.4 1.8 2.7 5.1 3 13.74 60.4 tt
68 MYTHREHI 25 F 43 18 0.7 7.8 1.1 3.5 6.7 4.9 8.95 55.5 tt
69 PANCHAVARNAM 54 F 58 30 0.8 10.2 1 3 6.4 4.3 31 57.6 tt
70 ISAQBASHA 32 M 43 15 0.8 8.7 1.1 2.8 6.7 4.1 13.58 40.5 tt
71 RANI 54 F 64 24 0.7 7.8 1.1 3.7 8.1 5.2 7.45 61.9 tt
72 AMUDHA 45 F 53 12 0.7 7.4 1 2.4 6.5 3.7 9.45 75.6 tt
73 KOKILA.B 42 F 67 15 0.8 10.3 1.2 3.5 7.2 4.5 21.85 62 tt
74 SHYMALA 47 F 55 20 0.9 7.5 1.1 3 8.3 4.2 14.3 34.2      Tt
75 PORKODI 38 F 55 12 0.7 7.9 1.2 3 8 4.5 11.76 78.6 tt
76 KALPANA 36 F 33 16 0.9 7.7 1.1 5 5.4 3.6 10.28 78.6 tt
77 MAHESH 40 M 48 11 0.6 8.4 1.1 5.6 5.9 3.9 5.09 70.2 tt
78 REGINA 25 F 40 13 0.6 10.2 1.2 2.8 7.3 4.6 22.86 30.4 tt
79 AMUDHA.B 37 F 118 10 0.7 11.3 1.2 2.8 9.8 4.3 38.2 36.8 tt
80 LEELAVATHY 50 F 29 15 0.5 8.8 1.2 3.2 8.3 4.3 11.82 71.8 tt
81 KRISHNAVENI 28 F 32 17 0.7 7.9 1.2 4.9 8 4.8 9.81 45.2 tt
82 SHREELAKSHMI 25 F 45 11 0.5 6.8 1.1 4.9 7.3 4.2 10.89 40.6 tt
83 KANMANI 48 F 67 13 0.7 10.3 1.1 3.6 6.7 4.4 14.82 35.7 tt
84 DHIVIYA 26 F 30 17 0.8 9.1 1.1 4.3 7.1 3.8 15.93 55.3 tt
85 USHA 45 F 76 20 0.9 8 1.1 4.4 6.1 4.2 7.53 66.2 tt
86 VIMALI 29 F 86 19 1 8.5 1.1 4.3 6.2 3.4 10.29 95 tt
87 AROKYA 43 F 67 24 0.5 8.7 1.1 2.6 6.5 3.8 5.57 85.3 tt
88 RAMANI 43 F 78 15 0.7 8.2 1 3.5 8 4.6 10.25 33.1 tt
89 JAIKUMAR 42 M 66 12 0.8 8.9 1.2 3.8 6.7 4.6 17.85 21.8 tt
90 PREMKUMAR 35 M 98 14 0.7 11.3 1.1 3.5 7.2 2.9 22.97 65.5 tt
91 AROKYADAS 53 M 62 24 0.9 9.4 1.1 2.4 4.7 4.2 14.12 49.5 tt
92 JAMUNA 44 F 48 10 0.4 7.2 1.1 3.5 5.8 3.7 12.73 89.2 tt
93 DEVI 29 F 57 17 0.7 11.6 1.1 3.8 7 4.4 33.01 62.5 tt
94 SIVA.V 38 M 27 16 0.9 11.6 1.2 3.2 6.5 5.1 31.86 11.6 tt
95 NAGA 51 F 28 24 0.9 10.5 1.2 3.7 8.4 4.5 30.78 19.6 tt
96 VIJAYAN 39 46 18 0.8 9.5 1.2 4.4 7.1 4.5 23.71 55.1 tt
97 PRAKASH 34 M 38 23 1.2 9.3 1.1 3.4 6.8 3.8 39.35 36.3 tt
98 BALA. 28 M 53 20 0.6 9 1.1 4.8 7.6 4.2 27.21 51.1 tt
99 RAJKUMAR 54 M 90 23 1 9.7 1.1 3.1 7.1 4.5 22.14 63.3 tt
100 REKHA. 33 F 48 13 0.7 7.5 1.1 3.8 6.8 4.7 5.54 51.8 tt
